[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 328
1. Zhao Y, Zong ZH, Xu HM: RhoC expression level is correlated with the clinicopathological characteristics of ovarian cancer and the expression levels of ROCK-I, VEGF, and MMP9. Gynecol Oncol; 2010 Mar;116(3):563-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RhoC expression level is correlated with the clinicopathological characteristics of ovarian cancer and the expression levels of ROCK-I, VEGF, and MMP9.
  • OBJECTIVE: To determine the clinicopathological significance of RhoC expression in human ovarian cancer and its effect on the expression of vascular endothelial growth factor (VEGF), Rho-associated coiled-coil-forming kinase (ROCK), and metal matrix proteinases (MMPs).
  • METHODS: Tissue samples from normal ovaries, benign ovarian tumors, and epithelial ovarian cancer were collected.
  • Small interfering RNA (siRNA) was also used to target RhoC expression in the OVCAR3 and CaOV3 ovarian cancer cell lines, after which cell invasion and migration assays were performed, and the expression of ROCK-I, VEGF, and MMP9 was evaluated.
  • RESULTS: The expression levels of RhoC, ROCK-I, VEGF, and MMP9 mRNA and protein were significantly higher in ovarian cancer, showing a correlation with clinical stage but not histological type.
  • CONCLUSION: The expression level of RhoC is correlated to clinical stage and vascularization in ovarian cancer.
  • [MeSH-major] Matrix Metalloproteinase 9 / biosynthesis. Ovarian Neoplasms / metabolism. Vascular Endothelial Growth Factor A / biosynthesis. rho GTP-Binding Proteins / biosynthesis. rho-Associated Kinases / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Cell Movement / physiology. Female. Humans. Matrix Metalloproteinase Inhibitors. Middle Aged. Neoplasm Invasiveness. Neovascularization, Pathologic / genetics. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. RNA, Small Interfering / administration & dosage. RNA, Small Interfering / genetics. Transfection. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20022093.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Matrix Metalloproteinase Inhibitors; 0 / RHOC protein, human; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.11.1 / rho-Associated Kinases; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.6.5.2 / rho GTP-Binding Proteins
  •  go-up   go-down


2. Jeschke U, Bischof A, Speer R, Briese V, Richter DU, Bergemann C, Mylonas I, Shabani N, Friese K, Karsten U: Development of monoclonal and polyclonal antibodies and an ELISA for the determination of glycodelin in human serum, amniotic fluid and cystic fluid of benign and malignant ovarian tumors. Anticancer Res; 2005 May-Jun;25(3A):1581-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of monoclonal and polyclonal antibodies and an ELISA for the determination of glycodelin in human serum, amniotic fluid and cystic fluid of benign and malignant ovarian tumors.
  • We also found significantly increased glycodelin concentrations in the fluids of malignant ovarian cysts compared to benign ovarian tumors (p<0.001).
  • Its most promising application is expected in the diagnosis of ovarian cancer.
  • [MeSH-major] Antibodies / immunology. Glycoproteins / analysis. Ovarian Neoplasms / chemistry. Pregnancy Proteins / analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033064.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies; 0 / Glycoproteins; 0 / PAEP protein, human; 0 / Pregnancy Proteins
  •  go-up   go-down


3. Hahm TS, Ham JS, Kang JY: Unilateral massive hydrothorax in a gynecologic patient with pseudo-Meigs' syndrome -A case report-. Korean J Anesthesiol; 2010 Feb;58(2):202-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pseudo-Meigs' syndrome is characterized by the presence of a benign ovarian tumor associated with ascites and a right-sided hydrothorax.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Obstet Gynaecol Res. 2005 Jun;31(3):257-62 [15916664.001]
  • [Cites] Obstet Gynecol. 1954 May;3(5):471-86 [13154792.001]
  • [Cites] Am J Obstet Gynecol. 1954 May;67(5):962-85 [13148256.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1999 Jan;82(1):97-9 [10192495.001]
  • [Cites] Chest Surg Clin N Am. 1998 May;8(2):449-72 [9619316.001]
  • [Cites] Am J Obstet Gynecol. 2001 Feb;184(3):354-5 [11228486.001]
  • [Cites] Kidney Int Suppl. 1993 Feb;40:S75-80 [8445842.001]
  • [Cites] J Clin Gastroenterol. 1988 Dec;10(6):663-6 [3068304.001]
  • [Cites] J R Soc Med. 1987 Apr;80(4):252-3 [3585894.001]
  • [Cites] Am J Obstet Gynecol. 1970 Jun 15;107(4):538-45 [4316407.001]
  • [Cites] Br J Anaesth. 2001 Sep;87(3):507-9 [11517142.001]
  • [Cites] Masui. 1997 Mar;46(3):413-5 [9095620.001]
  • (PMID = 20498801.001).
  • [ISSN] 2005-7563
  • [Journal-full-title] Korean journal of anesthesiology
  • [ISO-abbreviation] Korean J Anesthesiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2872861
  • [Keywords] NOTNLM ; Hydrothorax / Hypoxia / Pseudo-Meigs' syndrome
  •  go-up   go-down


Advertisement
4. Baksu B, Akyol A, Davas I, Yazgan A, Ozgul J, Tanik C: Recurrent mucinous cystadenoma in a 20-year-old woman: was hysterectomy inevitable? J Obstet Gynaecol Res; 2006 Dec;32(6):615-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A recurrence of ovarian mucinous cysts is very rare.
  • Over a period of 21 months, a 20-year-old patient had three laparotomies resulting initially in the removal of one ovary with a mucinous cystadenoma and two cystectomies for the same pathology, but ultimately leading to hysterectomy and salphingo-oopherectomy.
  • Because mucinous tumors are usually benign and most of the time multilocular, management of young patients is challenging, especially in the case of recurrence.
  • Follow-up of these patients is very important and transvaginal ultrasound seems to be currently the most effective diagnostic tool for the follow-up of young patients treated with cystectomy for benign mucinous cystadenomas.
  • [MeSH-major] Cystadenoma, Mucinous / surgery. Hysterectomy. Neoplasm Recurrence, Local / surgery. Ovarian Neoplasms / surgery. Ovariectomy

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17100827.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Schem Ch, Bauerschlag DO, Meinhold-Heerlein I, Fischer D, Friedrich M, Maass N: [Benign and borderline tumors of the ovary]. Ther Umsch; 2007 Jul;64(7):369-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign and borderline tumors of the ovary].
  • [Transliterated title] Benigne und Borderline-Tumoren des Ovars.
  • Palpable or sonographic ovarian tumors are reason for various differential diagnoses.
  • Therefore the clarification of ovarian lesions is one of the main duties in daily gynaecological practice.
  • Although diagnostic procedures might be supplemented by CT-Scan or MRI techniques, classical bimanual examination and vaginal ultrasound scan will determine the diagnosis in most cases comparably accurate.
  • The suspected diagnosis concerning benign or malignant lesions, should take the palpable and sonographic feature, as well as the information from the patients medical history (e.g. family history of malignant diseases (BRCA 1/2 mutations) into account.
  • They are mostly normal follicle cysts, but may also be a tumor of low malignant potential (LMP-tumor) or even an invasive cancerous lesion.
  • 20-30% of all ovarian tumors are malignant and by the time of primary diagnosis already in a about 60-70% incurable due to intraabdominal dissemination.
  • Benign or malignant lesions may occur in every age group.
  • Ovarian tumors at infantile age are malignant in about 15%.
  • Most malignant tumors occur between the age of 50 to 70.
  • The LMP-tumors occur in average 10 years earlier.
  • Malignant ovarian lesions represent about 15-30% of all genital malignant tumors.
  • The persistence of ovarian cysts and tumors will be mostly examined by laparoscopic surgery.
  • In that respect the diagnosis of LMP-tumors might be incidentally and will then have a substantial impact on the extent of the surgery and the follow up.
  • This compilation overviews the spectrum of benign and low malignant potential tumors of the ovary and their different tissues of origin.
  • [MeSH-major] Ovarian Neoplasms
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Recurrence, Local. Ovarian Cysts / diagnosis. Ovarian Cysts / radiography. Ovarian Cysts / ultrasonography. Ovary / pathology. Palpation. Time Factors. Tomography, X-Ray Computed. Ultrasonography, Doppler

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17948753.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 22
  •  go-up   go-down


6. Ma L, Liu FR, Zhang SL: [Detection of circulating hypermethylated tumor-specific RASSF1A DNA in ovarian cancer patients]. Zhonghua Bing Li Xue Za Zhi; 2005 Dec;34(12):785-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of circulating hypermethylated tumor-specific RASSF1A DNA in ovarian cancer patients].
  • OBJECTIVE: To detect hypermethylated tumor-specific RASSF1A DNA in the circulation and its significance in ovarian cancers patients.
  • METHODS: Methylation-specific polymerase chain reaction (MSP) was used to study the hypermethylation of RASSF1A in preoperative serum samples from 51 ovarian cancer patients.
  • RESULTS: The RASSF1A gene was not methylated in peripheral blood samples from 51 normal patients and 51 patients with benign ovarian tumors.
  • Hypermethylation of RASSF1A gene was found in circulating tumor-specific DNA in 43.1% of patients (22 out of 51 cases) with ovarian cancers (P < 0.05).
  • There was no difference in hypermethylation of RASSF1A gene amongst various ovarian cancer subtypes (P < 0.05).
  • On the other hand, hypermethylation of RASSF1A gene was more frequently encountered in stage III and IV than stage I and II tumors (P < 0.05).
  • CONCLUSIONS: There is a higher frequency of RASSF1A hypermethylation in circulating tumor-specific DNA of ovarian cancer patients.
  • RASSF1A has been postulated to play an important role as tumor suppressor gene and can be silenced by promoter hypermethylation.
  • Such observation may carry diagnostic and prognostic implications when assessing ovarian tumors.
  • [MeSH-major] DNA Methylation. Ovarian Neoplasms / blood. Tumor Suppressor Proteins / blood
  • [MeSH-minor] Carcinoma, Endometrioid / blood. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Mucinous / blood. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Serous / blood. Cystadenocarcinoma, Serous / pathology. Female. Humans. Neoplasm Staging

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16545186.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


7. Hein S, Mahner S, Kanowski C, Löning T, Jänicke F, Milde-Langosch K: Expression of Jun and Fos proteins in ovarian tumors of different malignant potential and in ovarian cancer cell lines. Oncol Rep; 2009 Jul;22(1):177-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Jun and Fos proteins in ovarian tumors of different malignant potential and in ovarian cancer cell lines.
  • They play a role in cell proliferation, malignant transformation and invasion in various tumors.
  • The aim of the current study was to characterize the role of AP-1 in ovarian cancer.
  • Fifty-six ovarian tumors of different invasive potential including 13 metastases as well as 5 ovarian cancer cell lines were analyzed by Western blot analysis regarding their expression of pc-Jun, Jun B, Jun D, c-Fos, Fos B, Fra-1 and Fra-2.
  • The expression of pc-Jun, Jun B, Jun D and Fra-2 was higher in invasive cancer compared to benign tumors.
  • In metastases, c-Fos and Fos B expression was significantly lower than in the respective primary ovarian carcinomas.
  • These results suggest that AP-1 proteins are differentially expressed in benign ovarian tumors, tumors with low malignant potential and epithelial ovarian carcinomas and metastases.
  • No correlation with the proliferative and invasive potential of ovarian cancer cell lines could be found.
  • [MeSH-major] Ovarian Neoplasms / metabolism. Proto-Oncogene Proteins c-fos / metabolism. Proto-Oncogene Proteins c-jun / metabolism. Transcription Factor AP-1 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Cell Movement. Cell Proliferation. Female. Fos-Related Antigen-2 / metabolism. Humans. Middle Aged. Neoplasm Invasiveness. Time Factors


8. Friel AM, Zhang L, Curley MD, Therrien VA, Sergent PA, Belden SE, Borger DR, Mohapatra G, Zukerberg LR, Foster R, Rueda BR: Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells. Reprod Biol Endocrinol; 2010;8:147
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Recent data provide significant evidence to support the hypothesis that there are sub-populations of cells within solid tumors that have an increased tumor initiating potential relative to the total tumor population.
  • CD133, a cell surface marker expressed on primitive cells of neural, hematopoietic, endothelial and epithelial lineages has been identified as a marker for tumor initiating cells in solid tumors of the brain, colon, pancreas, ovary and endometrium.
  • Our objectives were to assess the relative level of CD133 expressing cells in primary human endometrial tumors, confirm their tumorigenic potential, and determine whether CD133 expression was epigenetically modified.
  • METHODS: We assessed CD133 expression in primary human endometrial tumors by flow cytometry and analyzed the relative tumorigenicity of CD133+ and CD133- cells in an in vivo NOD/SCID mouse model.
  • We further examined CD133 promoter methylation and expression in normal endometrium and malignant tumors.
  • In addition, we confirmed the tumor initiating potential of CD133+ and CD133- cell fractions in NOD/SCID mice.
  • Interestingly, the percentage of CD133+ cells in human endometrial tumor xenografts, as evidenced by immunofluorescence, increased with serial transplantation although this trend was not consistently detected by flow cytometry.
  • To support this finding, we demonstrated that regions of the CD133 promoter were hypomethylated in malignant endometrial tissue relative to benign control endometrial tissue.
  • Lastly, we determined that methylation of the CD133 promoter decreases over serial transplantation of an endometrial tumor xenograft.
  • [MeSH-major] Antigens, CD / genetics. Cell Transformation, Neoplastic / pathology. Endometrial Neoplasms / pathology. Epigenomics. Glycoproteins / genetics. Neoplastic Stem Cells / pathology. Peptides / genetics
  • [MeSH-minor] Animals. Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Female. Humans. Mice. Mice, Inbred NOD. Mice, SCID. Neoplasm Transplantation

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Res. 2008 Oct;18(10):1037-46 [18679414.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):8094-103 [18829568.001]
  • [Cites] Cell Cycle. 2009 Jan 1;8(1):158-66 [19158483.001]
  • [Cites] Cancer Lett. 2009 Jun 28;279(1):13-21 [19232461.001]
  • [Cites] Biol Reprod. 2009 Jun;80(6):1136-45 [19228591.001]
  • [Cites] Anticancer Res. 2009 Jun;29(6):2235-7 [19528487.001]
  • [Cites] Clin Cancer Res. 2009 Jul 1;15(13):4299-311 [19509143.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] BMC Cancer. 2009;9:221 [19583859.001]
  • [Cites] Cancer Res. 2009 Nov 1;69(21):8241-8 [19843861.001]
  • [Cites] Stem Cells. 2009 Oct;27(10):2405-13 [19658191.001]
  • [Cites] Stem Cells. 2009 Dec;27(12):2875-83 [19816957.001]
  • [Cites] J Biochem. 2010 Sep;148(3):273-80 [20551139.001]
  • [Cites] Hum Pathol. 2010 Nov;41(11):1516-29 [20800872.001]
  • [Cites] Virchows Arch. 2004 Mar;444(3):213-23 [14747944.001]
  • [Cites] Mod Pathol. 2000 Mar;13(3):295-308 [10757340.001]
  • [Cites] Endocr Relat Cancer. 2000 Dec;7(4):227-42 [11174845.001]
  • [Cites] Breast Cancer Res. 2003;5(1):R1-8 [12559051.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2055-61 [14630820.001]
  • [Cites] Biol Reprod. 2004 Jun;70(6):1738-50 [14766732.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33 [15381773.001]
  • [Cites] Biol Reprod. 1989 Mar;40(3):681-90 [2758097.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5002-12 [9389720.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5013-21 [9389721.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Stem Cells. 2006 Jun;24(6):1529-38 [16456137.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4783-91 [17028294.001]
  • [Cites] Hum Reprod. 2007 Jan;22(1):45-51 [16923745.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Hum Reprod. 2007 May;22(5):1214-23 [17283036.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):479-85 [17762575.001]
  • [Cites] Cell Cycle. 2008 Jan 15;7(2):242-9 [18256549.001]
  • [Cites] Int J Gynecol Cancer. 2008 May-Jun;18(3):506-14 [17868344.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4311-20 [18519691.001]
  • [Cites] J Mol Med (Berl). 2008 Sep;86(9):1025-32 [18535813.001]
  • [Cites] Oncogene. 2009 Jan 15;28(2):209-18 [18836486.001]
  • (PMID = 21122138.001).
  • [ISSN] 1477-7827
  • [Journal-full-title] Reproductive biology and endocrinology : RB&E
  • [ISO-abbreviation] Reprod. Biol. Endocrinol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA098258; United States / NCI NIH HHS / CA / P50 CA098258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Peptides; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ PMC3027593
  •  go-up   go-down


9. Ma YX, Ye F, Chen HZ, Lü WG, Xie X: [Study of apoptosis and Fas expression of peritoneal fluid and peripheral blood T lymphocytes in patients with epithelial ovarian cancer and their relationship with CA125]. Zhonghua Yi Xue Za Zhi; 2007 Mar 20;87(11):734-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study of apoptosis and Fas expression of peritoneal fluid and peripheral blood T lymphocytes in patients with epithelial ovarian cancer and their relationship with CA125].
  • OBJECTIVE: To investigate the apoptosis and Fas (CD95) expression of T lymphocytes from the peripheral blood and peritoneal fluid of the patients with ovarian cancer and their relationship with CA125.
  • Peripheral blood samples were obtained from the following objects respectively: patients with stage III - IV ovarian cancer (n = 18) before and after treatment, patients with stage I - II ovarian cancer (n = 15), patients with benign ovarian tumor (n = 18), patients with Krukenberg tumor (n = 6) and normal control (n = 20).
  • Peritoneal fluids were obtained from all the patients with ovarian cancer, Krukenberg tumor and ten patients with benign ovarian tumor.
  • Level of serum CA125 of the patients with ovarian cancer was assessed.
  • RESULTS: In the patients with stage III - IV ovarian cancer, the apoptosis level of the peripheral blood T lymphocytes was 5.55 (3.57 - 9.62)%, significantly higher than those from the patients with stage I - II ovarian cancer, patients with benign ovarian tumor, controls (P < 0.008 in all instances) and the patients with stage III - IV ovarian cancer after treatment (P < 0.05).
  • The intensity of Fas expression of the peripheral blood T lymphocytes from the patients with stage III - IV ovarian cancer was 51 +/- 10, significantly higher than that from controls (P < 0.05).
  • In peritoneal fluid, the apoptosis rates of T lymphocytes, positive rate and intensity of Fas expression on T lymphocytes from patients with stage I - II and stage III - IV ovarian cancer were 17.41 (7.06 - 24.56)%, (57 +/- 16)%, (55 +/- 11)% and 34.06 (17.03 - 44.65)%, (66 +/- 12)%, (70 +/- 24)%, respectively, increased significantly compared with those from patients with benign ovarian tumor, which were 0.78 (0.67 - 1.44)%, (37 +/- 6)%, 43 +/- 6, respectively (P < 0.01 in all instances).
  • The apoptosis level and positive rate of Fas expression on peritoneal fluid T lymphocytes from patients with stage III - IV ovarian cancer were significantly higher than those from patients with Krukenberg tumor (P < 0.01).
  • There was a positive correlation between the serum CA125 level and the apoptosis level of peritoneal fluid T cell in the patients with stage I - II ovarian cancer (r = 0.77, P = 0.009).
  • For ovarian cancer, the apoptosis level of peritoneal fluid T lymphocytes from patients with the serum CA125 > 500 KU/L was higher than that from the patients with the serum CA125 < or = 500 KU/L (P = 0.009).
  • CONCLUSIONS:. (1) Extraordinarily increased apoptosis of T cells may play an important role in the development of systemic and celiac immunodeficiency in the patients with ovarian cancer.
  • In contrast with the patients with Krukenberg tumor, the patients with advanced ovarian cancer hare higher percentage of apoptotic peritoneal fluid T lymphocytes, which shows the particularity of local immunity defect. (2) For the patients with ovarian cancer, efficient treatment can decrease the percentage of apoptotic peripheral blood T lymphocytes. (3) The increased positive rate and intensity of Fas expression on peritoneal fluid T lymphocytes stressed the significance of Fas interference in the treatment of ovarian cancer. (4) Level of serum CA125 can reflect the celiac immunity defection in patients with ovarian cancer.
  • [MeSH-major] Antigens, CD95 / biosynthesis. Apoptosis. Ascitic Fluid / metabolism. CA-125 Antigen / biosynthesis. Ovarian Neoplasms / pathology. T-Lymphocytes / metabolism
  • [MeSH-minor] Adult. Fas Ligand Protein / biosynthesis. Female. Flow Cytometry. Humans. Middle Aged. Neoplasm Staging


10. Wang P, Wu X, Chen W, Liu J, Wang X: The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms. Gynecol Oncol; 2007 Mar;104(3):714-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms.
  • OBJECTIVE: To investigate the lysophosphatidic acid (LPA) receptors expression situation and their biological significance in human ovarian cancer cell lines and in human epithelial ovarian neoplasms.
  • METHODS: The reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting were employed to measure the expression levels of LPA(1), LPA(2) and LPA(3) mRNA, LPA(2) and LPA(3) protein expression in cultured human ovarian cancer cell lines (3AO, SKOV3 and OVCAR3) and in human epithelial ovarian neoplasms.
  • The immunocytochemical method was used to detect LPA(2) and LPA(3) protein expression in cultured human ovarian cancer cell lines.
  • RESULTS: RT-PCR revealed that all ovarian cancer cell lines expressed LPA(1), LPA(2) and LPA(3) mRNA.
  • The positive rates (100%; 86.4%; 88.2%) of LPA(1) mRNA in normal ovarian tissue, benign tumor and ovarian cancer were no significant difference (p>0.05).
  • The expression level of LPA(1) mRNA was significantly higher in normal ovarian tissue compared with that in benign tumor and in ovarian cancer tissue (p<0.01).
  • LPA(1) expression level was no significant difference in both benign tumor and ovarian cancer tissue (p>0.05).
  • LPA(2) mRNA-positive rates (92.6%) and expression level were significantly higher in ovarian cancer compared with that in benign tumor (31.8%) and in normal ovarian tissue (31.3%) (p<0.01); LPA(2) mRNA-positive rates and expression level were no significant difference in both benign tumor and normal ovarian tissue (p>0.05).
  • LPA(3) mRNA-positive rates (92.6%) and expression level were significantly higher in ovarian cancer compared with that in benign tumor (31.8%) and in normal ovarian tissue (31.3%) (p<0.01), LPA(3) mRNA-positive rates and expression level were no significant difference in both benign tumor and normal ovarian tissue (p>0.05).
  • LPA(1) mRNA expression level was significantly decreased compared with that of LPA(2) and LPA(3) in ovarian cancer (p<0.01); Western blotting clearly revealed that all ovarian cancer cell lines showed LPA(2) and LPA(3) protein.
  • The positive rates and expression level of LPA(2) and LPA(3) protein were significantly increased in ovarian cancer (92.6%; 92.6%) compared with that in benign tumor (45.5%; 45.5%) and that in normal ovarian tissue (43.8%; 43.8%) (p<0.01); LPA(2) and LPA(3) protein-positive rates and expression level were no significant difference in both benign tumor and normal ovarian tissue (p>0.05).
  • The mRNA and protein expression of LPA(2) and LPA(3) in stages III and IV was significantly higher than that in stages I and II epithelial ovarian cancer (p<0.05).
  • CONCLUSION: LPA(1), LPA(2) and LPA(3) mRNA and protein expressed widely in human epithelial ovarian neoplasms.
  • LPA(2) and LPA(3) may be involved in the development and progression of human ovarian cancer.
  • There was a significant correlation between LPA(2), LPA(3) and invasion and metastasis of epithelial ovarian cancer.
  • LPA(2) and LPA(3) may be a prognostic indicator in patients with epithelial ovarian cancer.
  • [MeSH-major] Ovarian Neoplasms / metabolism. Receptors, Lysophosphatidic Acid / biosynthesis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17204312.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Lysophosphatidic Acid
  •  go-up   go-down


11. Kikkawa F, Nawa A, Kajiyama H, Shibata K, Ino K, Nomura S: Clinical characteristics and prognosis of mucinous tumors of the ovary. Gynecol Oncol; 2006 Oct;103(1):171-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and prognosis of mucinous tumors of the ovary.
  • OBJECTIVE: Ovarian mucinous tumors consist of benign, borderline, and carcinomatous tumor, but the clinical characteristics of these 3 types have not been investigated in detail.
  • In this study, we compared the clinical characteristics and prognosis among these 3 types of mucinous tumors.
  • METHODS: One hundred sixty-one patients with mucinous cystadenocarcinoma and 143 patients with mucinous borderline tumor were registered between 1986 and 2003.
  • All patients were reviewed by two pathologists, then the mixed type and cases showing other organized malignant tumors were excluded from this study.
  • RESULTS: Mean patient ages were 43.9, 44.7, and 49.7 years in patients with benign, borderline, carcinomatous tumor, respectively.
  • The ratio of early stage (I, II) to advanced stage (III, IV) was significantly lower in carcinoma than in borderline tumor.
  • The levels of tumor markers tended to increase with the level of malignancy.
  • In borderline tumor, 5 patients died of disease, and all of these patients had stage III disease with residual tumor after the initial surgery.
  • Patients with borderline tumor showed significantly better prognosis than those with carcinoma; however, there were no significant differences in prognosis between borderline tumor and carcinoma in patients with stage III tumor or residual tumor.
  • CONCLUSIONS: In mucinous tumors, measurement of CA72-4 is recommended to distinguish malignant from benign tumors.
  • Even in borderline tumor, patients with residual tumor showed a poorer prognosis than carcinoma, suggesting that complete resection is necessary for a good prognosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Carboplatin / administration & dosage. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16546243.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


12. Daneshbod Y, Daneshbod K, Rasekhi AR, Mosayebi Z, Negahban S, Hodjati SR, Bedayat GR, Ganjei-Azar P: Cytologic differentiation of struma ovarii from other ovarian neoplasms. Acta Cytol; 2008 Jan-Feb;52(1):72-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic differentiation of struma ovarii from other ovarian neoplasms.
  • OBJECTIVE: To present the cytologic findings of struma ovarii and value of cytology and immunocytochemistry (ICC) using thyroglobulin (TGB) and thyroid transcription factor-1 (TTF-1) in evaluation of this unusual ovarian neoplasm, together with the diagnostic pitfalls.
  • RESULTS: The cases were divided in to 3 groups: group 1--diagnosis of struma ovarii was made by cytology and confirmed by ICC (1 case); group 2--diagnosis was suggestive on cytology or cell block and confirmed by ICC staining (4 cases); group 3--on cytologic diagnosis indistinguishable from other cystic ovarian neoplasms (2 cases).
  • Cytologic findings were typically colloid with mosaic pattern, follicles, follicular cells only, sheets of follicular cells, both colloid and follicular cells, proteinaceous background or degenerated epithelial cells indistinguishable from other cystic ovarian neoplasms.
  • CONCLUSION: Cytologic findings of struma ovarii are distinct enough to be suggested intraoperatively, and ICC for TGB or TTF-1 is a valuable tool for preoperative fine needle aspiration biopsy and intraoperative diagnosis of this benign ovarian neoplasm.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Ovarian Neoplasms / diagnosis. Struma Ovarii / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Nuclear Proteins / metabolism. Thyroglobulin / metabolism. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18323278.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


13. Kamat AA, Baldwin M, Urbauer D, Dang D, Han LY, Godwin A, Karlan BY, Simpson JL, Gershenson DM, Coleman RL, Bischoff FZ, Sood AK: Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. Cancer; 2010 Apr 15;116(8):1918-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker.
  • BACKGROUND: Cell-free DNA reflects both normal and tumor-derived DNA released into the circulation through cellular necrosis and apoptosis.
  • The authors sought to determine the role of preoperative total plasma cell-free DNA levels in predicting clinical outcome in patients with ovarian cancer.
  • METHODS: After institutional review board consent, DNA was extracted from plasma of 164 women with invasive epithelial ovarian carcinoma (EOC), 49 with benign ovarian neoplasms, and 75 age-matched controls.
  • In the training set, EOC patients had a median preoperative cell-free DNA level of 10,113 GE/mL, compared with patients with benign ovarian neoplasms (median, 2365 GE/mL; P < .0001) and controls (median, 1912 GE/mL, P < .0001).
  • Elevated plasma cell-free DNA is an independent predictor for death from disease in ovarian cancer.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 American Cancer Society.
  • [Cites] Ann N Y Acad Sci. 2000 Apr;906:161-8 [10818614.001]
  • [Cites] Transfusion. 2001 Feb;41(2):276-82 [11239235.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1659-65 [11245480.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2222-7 [11489795.001]
  • [Cites] Clin Chem. 2001 Sep;47(9):1607-13 [11514393.001]
  • [Cites] Anticancer Res. 2002 Jan-Feb;22(1A):421-5 [12017326.001]
  • [Cites] Clin Chim Acta. 2002 Jul;321(1-2):77-87 [12031596.001]
  • [Cites] Cancer Treat Rev. 2002 Oct;28(5):255-71 [12435372.001]
  • [Cites] J Natl Cancer Inst. 2002 Nov 20;94(22):1697-703 [12441325.001]
  • [Cites] Reprod Biomed Online. 2003 Apr-May;6(3):349-51 [12735873.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):288-91 [12872347.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3902-8 [14507943.001]
  • [Cites] Int J Gynecol Cancer. 2004 May-Jun;14(3):459-64 [15228418.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6476-81 [15374957.001]
  • [Cites] Head Neck. 2004 Oct;26(10):878-83 [15390201.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4157-64 [15483026.001]
  • [Cites] J Immunol Methods. 1975 Dec;9(2):157-64 [1206227.001]
  • [Cites] Eur J Cancer Clin Oncol. 1987 Jun;23(6):707-12 [3653190.001]
  • [Cites] Am J Obstet Gynecol. 1988 Aug;159(2):341-6 [2457318.001]
  • [Cites] Cancer Treat Rev. 1995 May;21(3):215-45 [7656266.001]
  • [Cites] Nat Med. 1996 Sep;2(9):1035-7 [8782464.001]
  • [Cites] J Clin Oncol. 1996 Nov;14(11):2968-75 [8918494.001]
  • [Cites] Am J Hum Genet. 1998 Apr;62(4):768-75 [9529358.001]
  • [Cites] Cancer Metastasis Rev. 1999;18(1):65-73 [10505546.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1141-5 [15734995.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1394-9 [15746038.001]
  • [Cites] Cancer Biol Ther. 2006 Oct;5(10):1369-74 [16969071.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Obstet Gynecol. 2008 Oct;112(4):843-50 [18827127.001]
  • (PMID = 20166213.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD050128; United States / NCI NIH HHS / CA / P50 CA083639-090008; United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / CA083639-090008; United States / NICHD NIH HHS / HD / K12 HD050128
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ NIHMS189699; NLM/ PMC2854845
  •  go-up   go-down


14. Yan XJ, Tian Y, Wang C, Wang XL, Di JM, Cheng JX: [The expressions and clinical significance of IGFBP-2, -3 in both serum and tumor tissues in patients with epithelial ovarian cancer]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jul;40(4):639-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The expressions and clinical significance of IGFBP-2, -3 in both serum and tumor tissues in patients with epithelial ovarian cancer].
  • OBJECTIVE: To explore the serum levels of IGFBP-2, -3 and their proper roles in the regulation of IGF-II bioavailability in patients with ovarian tumor, and to investigate the correlation between the expressions of IGFBP-2 and IGFBP-3 in ovarian tumor tissues and related clinicopathological characteristics.
  • METHODS: Serum levels of IGFBP-2, -3 and big/mature IGF-II were measured by Western ligand blot (WLB) and Western blot (WB) in patients with ovarian tumor (10 cases of benign tumor, 6 cases of borderline tumor and 10 cases of malignant tumor) and 10 cases of normal control.
  • The expressions of IGFBP-2 and IGFBP-3 were examined in 39 specimens of ovarian tumor (8 cases of benign tumor, 8 cases of borderline tumor and 23 cases of malignant tumor) and 4 cases of normal ovarian tissues by immunohistochemical staining.
  • RESULTS: The serum levels of both big and mature IGF-II in epithelial ovarian cancer (ovarian cancer) patients were significantly decreased compared with those of normal control and benign and borderline tumor (P<0.001 or P<0.01).
  • The increased serum level of IGFBP-2 and decreased IGFBP-3 level were observed in patients with malignant ovarian tumors by comparing with those of patients with normal controls, benign and borderline tumor (P<0.001 or P<0.01).
  • The expression of IGFBP-2 was significantly higher in malignant ovarian tumor tissues than those in normal control and benign ovarian tumors tissues (P<0.0001, P<0.001, and the expression of IGFBP-3 decreased significantly in lower differentiated ovarian cancer tissues compared with that in high and moderate differentiated ovarian cancer tissues (P<0. 05).
  • CONCLUION: IGFBP-2 predominantly presents in the circulation of malignant patients in contrast to IGFBP-3, which may result in altered bioavailability of IGF-II in ovarian cancer, leading to the progress of tumor.
  • The serum levels of both IGFBP-2 and IGFBP-3 and their expressions in tumor tissues are correlated with the clinicopathological characteristics of ovarian cancer patients.
  • Our findings suggest that the presence of new mechanisms in the regulation of IGF-II bioavailability, and provide the evidence for the possibility to use IGFBP-2/IGFBP-3 as biological markers in diagnosis and prognosis of ovarian cancer.
  • [MeSH-major] Insulin-Like Growth Factor Binding Protein 2 / blood. Insulin-Like Growth Factor Binding Protein 3 / blood. Insulin-Like Growth Factor II / analysis. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19764562.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / Insulin-Like Growth Factor Binding Protein 3; 67763-97-7 / Insulin-Like Growth Factor II
  •  go-up   go-down


15. Barwijuk AJ, Bonarek-Sztaba J: [Comparison of gas and gasless laparoscopy in the treatment of benign ovarian tumors]. Ginekol Pol; 2006 Jun;77(6):450-1, 454-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of gas and gasless laparoscopy in the treatment of benign ovarian tumors].
  • OBJECTIVES: The aim of the study was to compare the outcomes of the gas and gasless laparoscopy in the treatment of benign ovarian tumors.
  • An ovarian tumor considered to be benign was the indication to operation.
  • Those assessments revealed that all tumors had been benign.
  • [MeSH-major] Laparoscopy / methods. Ovarian Neoplasms / surgery. Pneumoperitoneum, Artificial / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. Carbon dioxide .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16964696.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 142M471B3J / Carbon Dioxide
  •  go-up   go-down


16. Bi SN, Dai SZ, Yao Q, Che YC, Wang N: [Expression of mesothelin mRNA and protein in ovarian carcinomas]. Zhonghua Zhong Liu Za Zhi; 2008 Apr;30(4):288-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of mesothelin mRNA and protein in ovarian carcinomas].
  • OBJECTIVE: To investigate the expression of mesothelin (MESO) mRNA and protein and its significance in ovarian carcinomas.
  • METHODS: Semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemistry were used to detect the expression level of MESO mRNA and protein, respectively, in 124 samples of ovarian tumor and normal tissues, including 84 epithelial ovarian carcinomas, 12 borderline ovarian tumors, 16 benign ovarian tumors and 12 normal ovarian tissues.
  • RESULTS: The expression of MESO mRNA and protein in epithelial ovarian carcinomas (1.4005 +/- 0.4646, 2.7857 +/- 2.2712) and borderline ovarian tumors (1.0650 +/- 0.3100, 2.9167 +/- 2.391) were significantly higher than that in benign ovarian tumors (0.6463 +/- 0.2419, 1.2500 +/- 1.6125) and normal ovarian tissues (0.6439 +/- 0.2729, 0.9167 +/- 1.2401) (P < 0.05), and also significantly higher in serous cystadenocarcinoma (1.5255 +/- 0.4151, 3.3036 +/- 2.6141) and endometrioid carcinoma (1.5250 +/- 0.5419, 3.0000 +/- 2.3094) than that in mucinous cystadenocarcinoma (1.0675 +/- 0.3149, 1.0556 +/- 1.9242) (P < 0.05).
  • CONCLUSION: The results of this study demonstrated that the expression of MESO mRNA and protein is increased in ovarian carcinomas and borderline ovarian tumors, and MESO may play a role in the adhesion and dissemination of ovarian carcinomas.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Serous / metabolism. Membrane Glycoproteins / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Case-Control Studies. Female. GPI-Linked Proteins. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Ovary / metabolism. Ovary / pathology. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18788634.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / RNA, Messenger; 0 / mesothelin
  •  go-up   go-down


17. Porpora MG, Pallante D, Ferro A, Alò PL, Cosmi EV: Asymptomatic struma ovarii: a case report. Clin Exp Obstet Gynecol; 2005;32(3):197-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Struma ovarii is a rare ovarian neoplasm.
  • This tumor is generally benign, although malignant transformation has been reported.
  • The preoperative diagnosis is generally difficult.
  • We report a case of a 39-year-old woman who underwent laparoscopic resection of an asymptomatic right ovarian mass.
  • The pathologic diagnosis was struma ovarii.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / surgery. Struma Ovarii / diagnosis. Struma Ovarii / surgery
  • [MeSH-minor] Adult. Female. Humans. Laparoscopy. Ovary / surgery. Ovary / ultrasonography. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16433164.001).
  • [ISSN] 0390-6663
  • [Journal-full-title] Clinical and experimental obstetrics & gynecology
  • [ISO-abbreviation] Clin Exp Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


18. Mittal S, Gupta N, Sharma AK, Dadhwal V: Laparoscopic management of a large recurrent benign mucinous cystadenoma of the ovary. Arch Gynecol Obstet; 2008 Apr;277(4):379-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic management of a large recurrent benign mucinous cystadenoma of the ovary.
  • INTRODUCTION: Benign mucinous cystadenomas account for 15% of all ovarian neoplasms and up to 80% of all mucinous tumors.
  • Laparoscopy has become an accepted method of management for ovarian cysts and its role is expanding as large benign adnexal masses more than 10 cm can be managed safely and effectively.
  • CASE REPORT: We report a 25-year-old nulliparous lady with a huge benign mucinous cystadenoma managed by laparoscopic cystectomy, followed by an early recurrence within 2 months.
  • Pathology revealed a benign cyst.
  • CONCLUSION: Since mucinous tumors are usually benign and multilocular, management of young patients is challenging, especially in the case of recurrence which is very rare.
  • [MeSH-major] Cystadenoma, Mucinous / surgery. Laparoscopy / methods. Neoplasm Recurrence, Local / surgery. Ovarian Neoplasms / surgery. Ovariectomy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18236062.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  •  go-up   go-down


19. Witczak K, Szpurek D, Moszyński R, Sroka Ł, Sajdak S: [Clinical assessment of selected vascularization attributes of adnexal masses in preoperative prediction of tumor malignancy]. Ginekol Pol; 2007 May;78(5):373-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical assessment of selected vascularization attributes of adnexal masses in preoperative prediction of tumor malignancy].
  • OVERVIEW: Preoperative differential diagnosis of adnexal masses has been a challenge for researchers for years.
  • Prediction of tumor malignancy is essential for selection of optimal treatment with lowest risk for patient.
  • Assessment of various tumor vascularization attributes, using color Doppler semi-quantitative analysis, can be helpful for malignancy differentiation.
  • OBJECTIVES: To assess value of selected vascularization attributes of adnexal masses in preoperative prediction of tumor malignancy.
  • MATERIALS AND METHODS: This study included 521 women diagnosed and treated for adnexal masses (181 malignant and 340 benign) in Obstetrics and Gynecology Hospital of University of Medical Sciences in Poznan between 1994 and 2004.
  • RESULTS: There was a significantly higher number of vessels (cut-off value=4; p < 0.0001), central vessels localization (p < 0.0001) and irregular structure of vessels (p < 0.0001) in patients with confirmed malignant tumor.
  • CONCLUSIONS: Central vessels localization was the single most significant attribute in tumor malignancy differentiation.
  • [MeSH-major] Neovascularization, Pathologic / diagnostic imaging. Ovarian Neoplasms / blood supply. Ovarian Neoplasms / diagnostic imaging. Ovary / blood supply
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Staging. Ovarian Diseases / blood. Ovarian Diseases / diagnostic imaging. Poland. Predictive Value of Tests. ROC Curve. Retrospective Studies. Sensitivity and Specificity. Ultrasonography, Doppler, Color

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17867328.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


20. Coronado Martín PJ, Fasero Laiz M, García Santos J, Ramírez Mena M, Vidart Aragón JA: [Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer]. Med Clin (Barc); 2007 Jan 13;128(1):1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer].
  • [Transliterated title] Grado de expresión y valor pronóstico de las proteínas p53 y HER2/neu en el tejido ovárico benigno y en el cáncer de ovario.
  • BACKGROUND AND OBJECTIVE: To investigate the prognostic value of p53 and HER2/neu overexpression in epithelial ovarian cancer (EOC).
  • PATIENTS AND METHOD: p53 and HER2/neu immunostaining were performed in 198 tissue samples, 124 EOC, 44 benign ovarian tumors and 30 normal ovaries.
  • RESULTS: Neither p53 nor HER2/neu overexpression was seen in the benign ovarian tumors.
  • HER2/neu immunostaining was observed in one normal ovary.
  • [MeSH-major] Cystadenoma, Mucinous / genetics. Cystadenoma, Serous / genetics. Ovarian Neoplasms / genetics. Receptor, ErbB-2 / genetics. Teratoma / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Aged. Biomarkers, Tumor. Confidence Intervals. Endometriosis / genetics. Endometriosis / pathology. Endometriosis / surgery. Female. Follow-Up Studies. Genes, p53. Humans. Immunohistochemistry. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Ovarian Diseases / genetics. Ovarian Diseases / pathology. Ovarian Diseases / surgery. Prognosis. Proportional Hazards Models. Risk. Survival Analysis. Time Factors


21. Winter LM, Sommer G, Bongartz G: High-field magnetic resonance imaging of the pelvis: uterus, ovary, and prostate gland. Top Magn Reson Imaging; 2010 Jun;21(3):177-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-field magnetic resonance imaging of the pelvis: uterus, ovary, and prostate gland.
  • It has given proof of its usefulness in the diagnosis of several benign and malignant disorders, and it is routinely used for the local staging of different tumors even when confined to specific parts of a pelvic organ.
  • Definition of high field seems fuzzy because of the availability of MRI machines with 3, 7 T, or higher; therefore, the general aspects of MRI of pelvic structures with emphasis on uterus, ovary, and prostate gland and attention to promising newer techniques such as 3 T, dynamic contrast imaging, and diffusion-weighted imaging are reviewed in this article.
  • [MeSH-major] Imaging, Three-Dimensional / methods. Magnetic Resonance Imaging / methods. Pelvic Neoplasms / diagnosis. Radiographic Image Enhancement
  • [MeSH-minor] Diffusion Magnetic Resonance Imaging / methods. Diffusion Magnetic Resonance Imaging / trends. Female. Forecasting. Humans. Male. Neoplasm Invasiveness / pathology. Neoplasm Staging. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / pathology. Radiation Effects. Risk Assessment. Sensitivity and Specificity. Signal-To-Noise Ratio. Uterine Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21847037.001).
  • [ISSN] 1536-1004
  • [Journal-full-title] Topics in magnetic resonance imaging : TMRI
  • [ISO-abbreviation] Top Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


22. Tarkowski R, Polak G, Nowakowski A, Wertel I, Kotarski J: [YB-1 protein expression in ovarian cancer]. Ginekol Pol; 2006 Jun;77(6):458-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [YB-1 protein expression in ovarian cancer].
  • OBJECTIVES: Unfavourable prognosis of ovarian cancer is due to prompt progression, advanced stage at time of diagnosis and chemoresistance.
  • No protein tissue prognosticators of ovarian cancer are in clinical use yet.
  • High expression of YB-1 in tumour tissue correlates with unfavourable prognosis and chemoresistance in some malignant neoplasms.
  • THE AIM: of this study was to determine the expression of YB-1 in benign and malignant ovarian neoplasms and to correlate the expression of YB-1 with clinical indicators of cancer progression.
  • METHODS: Specimens of 11 benign ovarian cysts and 14 cystadenocarcinomas of the ovary were obtained.YB-1 expression was determined by immunohistochemistry.
  • Staging of ovarian cancer was performed according to FIGO.
  • RESULTS: Mean YB-1 expression levels in benign and malignant tumours were 5.36 +/- 4.1 and 2.86 +/- 4.18 points respectively and were not significantly different (p=0.18).
  • No correlation between FIGO stage and expression of YB-1 was found in the group of ovarian cancers, either (p=0.32).
  • CONCLUSIONS: This study demonstrates that YB-1 is expressed both in benign and malignant ovarian tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cell Transformation, Neoplastic / metabolism. Ovarian Cysts / chemistry. Ovarian Neoplasms / chemistry. Y-Box-Binding Protein 1 / analysis
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Neoplasm Staging

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cysts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16964697.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Y-Box-Binding Protein 1
  •  go-up   go-down


23. Song T, Choi CH, Lee YY, Kim TJ, Lee JW, Bae DS, Kim BG: Pediatric borderline ovarian tumors: a retrospective analysis. J Pediatr Surg; 2010 Oct;45(10):1955-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric borderline ovarian tumors: a retrospective analysis.
  • BACKGROUND/PURPOSE: Borderline ovarian tumors (BOTs) are uncommon in the pediatric population, and there have been limited studies that have included a small number of patients.
  • RESULTS: Twenty-nine patients (median age, 18 years) had a large-sized tumor (median, 19.8 cm).
  • The permanent section histology revealed 25 mucinous (86.2%) and 4 serous type tumors (13.8%).
  • In 2 cases, the suspected recurrences were found to be other benign ovarian tumors.
  • In one case that was initially treated with left ovarian cystectomy for a mucinous BOT, subsequent left salpingo-oophorectomy confirmed recurrence of a mucinous BOT at 16-month follow-up.
  • The last case was a newly developed primary ovarian mucinous carcinoma with no evidence of recurrence of a previous mucinous BOT at 26-month follow-up.
  • [MeSH-major] Cystadenoma, Mucinous / pathology. Cystadenoma, Mucinous / surgery. Cystadenoma, Serous / pathology. Cystadenoma, Serous / surgery. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Age Factors. Child. Female. Humans. Infertility, Female / prevention & control. Ovariectomy / adverse effects. Ovariectomy / methods. Ovary / pathology. Ovary / surgery. Retrospective Studies. Salpingectomy / methods. Treatment Outcome. Tumor Burden

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20920712.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Exacoustos C, Romanini ME, Rinaldo D, Amoroso C, Szabolcs B, Zupi E, Arduini D: Preoperative sonographic features of borderline ovarian tumors. Ultrasound Obstet Gynecol; 2005 Jan;25(1):50-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative sonographic features of borderline ovarian tumors.
  • OBJECTIVE: To determine the sonographic findings that distinguish borderline ovarian tumors (BOT) from both benign and invasive malignant tumors, thus allowing conservative treatment and laparoscopic management of these tumors.
  • We compared these findings with those of 337 patients with benign ovarian tumors and those of 82 patients with invasive malignant ovarian tumors.
  • The presence of papillae, defined as a small number of solid tissue projections, 1-15 mm in height and 1-10 mm in width (base) and length (base), into the cyst cavity from the cyst wall, was significantly more frequent in BOT (48%) than it was in benign (4%) and invasive (4%) malignant tumors.
  • Intracystic solid tissue (> 15 mm in height or > 10 mm in width or length) was observed in 48% of invasive malignant masses but in only 18% of BOT and in 7% of benign tumors (P < 0.001).
  • [MeSH-major] Ovarian Neoplasms / surgery. Ovarian Neoplasms / ultrasonography. Preoperative Care / methods
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Mucinous / ultrasonography. Adolescent. Adult. Aged. Aged, 80 and over. Child. Cystadenoma, Serous / pathology. Cystadenoma, Serous / surgery. Cystadenoma, Serous / ultrasonography. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Invasiveness. Postmenopause. Premenopause. Retrospective Studies. Sensitivity and Specificity. Ultrasonography, Doppler / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2004 ISUOG.
  • (PMID = 15619309.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


25. Mao HL, Liu PS, Zheng JF, Zhang PH, Zhou LG, Xin G, Liu C: Transfection of Smac/DIABLO sensitizes drug-resistant tumor cells to TRAIL or paclitaxel-induced apoptosis in vitro. Pharmacol Res; 2007 Dec;56(6):483-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transfection of Smac/DIABLO sensitizes drug-resistant tumor cells to TRAIL or paclitaxel-induced apoptosis in vitro.
  • In this study, we observed depressed Smac/DIABLO and increased XIAP expression in ovarian epithelial tissues ordered by normal, benign and malignant epithelia.
  • In epithelial ovarian cancer (EOC), the expression of Smac/DIABLO decreased with the malignancy.
  • Thus, over-expression of Smac/DIABLO is a promising strategy for drug-resistant ovarian cancer treatment.
  • [MeSH-major] Drug Resistance, Neoplasm. Intracellular Signaling Peptides and Proteins / genetics. Mitochondrial Proteins / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Adult. Antineoplastic Agents / pharmacology. Apoptosis. Cell Line, Tumor. Female. Humans. Middle Aged. Ovary / metabolism. Paclitaxel / pharmacology. RNA, Messenger / metabolism. TNF-Related Apoptosis-Inducing Ligand / pharmacology. Transfection. X-Linked Inhibitor of Apoptosis Protein / genetics. X-Linked Inhibitor of Apoptosis Protein / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18029193.001).
  • [ISSN] 1043-6618
  • [Journal-full-title] Pharmacological research
  • [ISO-abbreviation] Pharmacol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DIABLO protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Mitochondrial Proteins; 0 / RNA, Messenger; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XIAP protein, human; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


26. Wang Y, Yang J, Gao Y, Zhao XL, Li HZ, Yao Z: [Relationship between raf kinase inhibitor protein and metastasis of ovarian carcinoma]. Zhonghua Fu Chan Ke Za Zhi; 2009 Jul;44(7):522-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship between raf kinase inhibitor protein and metastasis of ovarian carcinoma].
  • OBJECTIVE: To investigate the relationship between raf kinase inhibitor protein (RKIP), a novel metastasis suppressor gene, and metastasis of ovarian carcinoma.
  • METHODS: Immunohistochemistry, RT-PCR, and western blot analysis were performed to examine the expression of RKIP in clinical samples of ovarian tumors and five human ovarian carcinoma cell lines.
  • Stable cell lines over-expressed or deleted of RKIP were cloned to investigate the function of RKIP in ovarian cancer cells.
  • The recombinant plasmids expressing sense (ss) or antisense (as) RKIP cDNA or empty vector was transfected into ovarian cancer cell line SKOV3 by lipofectamine.
  • The expression level of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) and extracellular signal-regulated kinase (ERK) in ovarian cancer cells were detected by western blot analysis.
  • (1) The expression levels of RKIP protein in ovarian carcinoma tissues from patients were found to be reduced than those in ovarian benign tumor and borderline tumor.
  • SKOV3 clones stably expressing full-length recombinant ssRKIP, asRKIP, and their respective empty vector were obtained. (2) RKIP was able to block basal levels of MEK and ERK in ovarian cancer cells.
  • CONCLUSION: RKIP could inhibits the metastasis, but also the growth of ovarian cancer cells. patients were found to be reduced than those in ovarian benign tumor and borderline tumor.
  • SKOV3 clones stably expressing full-length recombinant ssRKIP, asRKIP, and their respective empty vector were obtained. (2) RKIP was able to block basal levels of MEK and ERK in ovarian cancer cells.
  • CONCLUSION: RKIP could inhibits the metastasis, but also the growth of ovarian cancer cells.
  • [MeSH-major] Extracellular Signal-Regulated MAP Kinases / metabolism. Mitogen-Activated Protein Kinase Kinases / metabolism. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Phosphatidylethanolamine Binding Protein / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Line, Tumor. Cell Proliferation. Female. Genes, Tumor Suppressor. Genetic Vectors. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Phosphorylation. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transfection. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19957553.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Phosphatidylethanolamine Binding Protein; 0 / RNA, Messenger; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases
  •  go-up   go-down


27. Steffensen KD, Waldstrøm M, Andersen RF, Olsen DA, Jeppesen U, Knudsen HJ, Brandslund I, Jakobsen A: Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors. Int J Oncol; 2008 Jul;33(1):195-204
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors.
  • The epidermal growth factor receptors, HER1, HER2, HER3 and HER4 play a key role in the growth of malignant tumors.
  • The receptors of the EGF receptor family are not cancer-specific proteins since these receptors are expressed to some extent in both normal and benign tissue, but this is not elucidated in detail in ovarian tissue.
  • High tumor-to-normal-tissue concentration ratios would be favorable for molecular targeted anti-cancer treatment.
  • The primary aim of the study was to analyze the potential differential protein content and gene expression of the four receptors in benign and malignant ovarian tumors.
  • Tissue from 207 patients (101 malignant, 19 borderline, 64 benign ovarian tumors and 23 normal ovaries) were analyzed by quantitative ELISA for HER1-HER4 protein concentrations and by real-time PCR for HER1-HER4 gene expression.
  • The HER2-4 receptor protein content and the median gene expression level was significantly higher in ovarian cancer patients compared to patients with benign ovarian tumors and normal ovaries (p<0.0000001).
  • The protein content of the HER1 receptor was significantly lower in ovarian cancer compared to borderline tumors (p=0.012), benign ovarian tumors (p=0.049) and to normal ovaries (p=0.000069).
  • In conclusion, decreased concentration of HER1 protein and increased HER2, HER3 and HER4 protein concentration were observed, as also elevated HER2-HER4 gene expression levels in ovarian cancer patients with barely any overlap of the HER3 and HER4 expression in malignant ovarian tumors compared to benign ovarian tissues.
  • [MeSH-major] Ovarian Neoplasms / chemistry. Receptor, Epidermal Growth Factor / analysis. Receptor, ErbB-2 / analysis. Receptor, ErbB-3 / analysis


28. Cai Y, Shao SL, Wang QH, Yan LJ, Wang XY, Wang LX: [Expression and significance of GLUT-1 and DNA-PKcs in serous ovarian tumors]. Ai Zheng; 2007 Nov;26(11):1188-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and significance of GLUT-1 and DNA-PKcs in serous ovarian tumors].
  • This study was to evaluate the expression and biologic significance of GLUT-1 and DNA-PKcs in serous ovarian tumors.
  • METHODS: The expression of GLUT-1 and DNA-PKcs in 20 specimens of normal ovarian tissues, 20 specimens of serous cystadenoma, 20 specimens of borderline serous cystadenoma, and 40 specimens of serous cystadenocarcinoma were detected by SP immunohistochemistry.
  • The correlation of GLUT-1 and DNA-Pkcs expression to clinicopathologic characteristics of serous ovarian tumors was analyzed by Chi-square test.
  • RESULTS: The positive rate of GLUT-1 was significantly higher in malignant and borderline serous ovarian carcinomas than in benign tumors and normal ovarian tissues (100% and 55% vs. 0% and 0%, P<0.01).
  • The differences in the positive rate of DNA-PKcs were significant among normal ovarian tissues, benign, borderline, and malignant serous ovarian tumors (100%, 95%, 90%, and 60%, P<0.01).
  • GLUT-1 expression in borderline and malignant serous ovarian tumors was related to intraperitoneal implants, ascites, lymph node metastasis, and FIGO stage, but DNA-PKcs was only related to FIGO stage and lymph node metastasis (P<0.05).
  • CONCLUSION: The expression of GLUT-1 and the loss of DNA-PKcs may be closely related to the malignant transformation of serous ovarian tumors.
  • [MeSH-major] Cystadenocarcinoma, Serous / metabolism. Cystadenoma, Serous / metabolism. DNA-Activated Protein Kinase / metabolism. Glucose Transporter Type 1 / metabolism. Nuclear Proteins / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Chi-Square Distribution. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Ovary / metabolism. Ovary / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991316.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / Nuclear Proteins; EC 2.7.11.1 / DNA-Activated Protein Kinase; EC 2.7.11.1 / PRKDC protein, human
  •  go-up   go-down


29. Medeiros LR, Stein AT, Fachel J, Garry R, Furness S: Laparoscopy versus laparotomy for benign ovarian tumor: a systematic review and meta-analysis. Int J Gynecol Cancer; 2008 May-Jun;18(3):387-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopy versus laparotomy for benign ovarian tumor: a systematic review and meta-analysis.
  • To determine the efficacy, safety, and cost of laparoscopic surgery compared with laparotomy in women with ovarian tumors assumed to be benign.
  • [MeSH-major] Laparoscopy / methods. Laparotomy / methods. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Ovariectomy / methods
  • [MeSH-minor] Aged. Biopsy, Needle. Cost-Benefit Analysis. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Length of Stay. Middle Aged. Pain, Postoperative / physiopathology. Randomized Controlled Trials as Topic. Risk Assessment. Survival Rate. Treatment Outcome. United States

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17692084.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] United States
  • [Number-of-references] 38
  •  go-up   go-down


30. Ceauşu M, Terzea D, Georgescu A, Dobrea C, Mihai M, Iosif C, Vasilescu F, Ardeleanu C: Transitional cell tumors of the ovary: a compact group with a heterogeneous histological and immunophenotypical pattern. Rom J Morphol Embryol; 2008;49(4):513-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell tumors of the ovary: a compact group with a heterogeneous histological and immunophenotypical pattern.
  • A small percentage of ovarian neoplasms are transitional cell tumors, which proves to be a distinct group with various histological and immunohistochemical patterns.
  • In this study, 13 archived formalin-fixed paraffin-embedded samples of transitional cell tumors of the ovary have been assessed using standard HE stain and the indirect tristadial ABC peroxidase IHC method for 11 antibodies (CA125, CK7, CEA, EMA, MNF116, CK20, Vim, ER, PgR, PCNA, Ki-67).
  • More than 50% were malignant Brenner tumors.
  • CA125 was positive in all malignant tumors (of Brenner type and transitional cell carcinomas), but not in benign and borderline tumors, while CK7 was positive in approximately 70% of all cases.
  • A direct correlation statistically significant has been noted between the aforementioned proliferation factors and the tumor grade (r = 0.4, p = 0.05).
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Brenner Tumor / metabolism. Brenner Tumor / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Phenotype


31. Hu Y, Rosen DG, Zhou Y, Feng L, Yang G, Liu J, Huang P: Mitochondrial manganese-superoxide dismutase expression in ovarian cancer: role in cell proliferation and response to oxidative stress. J Biol Chem; 2005 Nov 25;280(47):39485-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitochondrial manganese-superoxide dismutase expression in ovarian cancer: role in cell proliferation and response to oxidative stress.
  • The manganese-containing SOD (Mn-SOD) has been suggested to have tumor suppressor function and is located in the mitochondria where the majority of O(2)(-) is generated during respiration.
  • The present study used a human tissue microarray to analyze Mn-SOD expression in primary ovarian cancer tissues, benign ovarian lesions, and normal ovary epithelium.
  • In experimental systems, suppression of Mn-SOD expression by small interfering RNA caused a 70% increase of superoxide in ovarian cancer cells, leading to stimulation of cell proliferation in vitro and more aggressive tumor growth in vivo.
  • Our findings suggest that the increase in Mn-SOD expression in ovarian cancer is a cellular response to intrinsic ROS stress and that scavenging of superoxide by SOD may alleviate the ROS stress and thus reduce the simulating effect of ROS on cell growth.
  • [MeSH-major] Ovarian Neoplasms / enzymology. Ovarian Neoplasms / genetics. Superoxide Dismutase / genetics
  • [MeSH-minor] Animals. Base Sequence. Cell Line, Tumor. Cell Proliferation. Cystadenoma / enzymology. Cystadenoma / genetics. Cystadenoma / pathology. Female. Gene Expression Profiling. Humans. Mice. Mitochondria / enzymology. Oligonucleotide Array Sequence Analysis. Ovary / cytology. Ovary / enzymology. Oxidative Stress. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. RNA, Small Interfering / genetics. Transfection

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16179351.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA100428; United States / NCI NIH HHS / CA / CA109041; United States / NCI NIH HHS / CA / CA85563
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / RNA, Small Interfering; EC 1.15.1.1 / Superoxide Dismutase
  •  go-up   go-down


32. Litkouhi B, Litkouhi B, Fleming E, Welch WR, Berkowitz RS, Birrer MJ, Mok SC: Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasms. Gynecol Oncol; 2008 May;109(2):234-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasms.
  • OBJECTIVE: Identifying markers specific for mucinous ovarian neoplasms (MON) is important for cancer diagnosis and surveillance, and will help improve our general understanding of the pathobiology of these tumors.
  • METHODS: Western blot compared CEACAM6 expression in normal human ovarian surface epithelium (HOSE) and ovarian cancer cell lines.
  • Quantitative RT-PCR (qRT-PCR) was performed on 75 laser-microdissected HOSE and ovarian cancer tissue samples.
  • 100-fold CEACAM6 overexpression (qRT-PCR) was demonstrated in 13/16 (81%) borderline, low-grade, and high-grade invasive MON's, compared to 5/50 (10%) serous and 1/5 (20%) benign mucinous samples.
  • CEACAM6 expression was not different between borderline and invasive MON's (p=0.55) or across tumor stage (p=0.76).
  • None of the serous or benign mucinous tumors exhibited CEACAM6 staining.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Antigens, CD / metabolism. Cell Adhesion Molecules / metabolism. Neoplasm Invasiveness. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / metabolism. Blotting, Western. Cell Line, Tumor. Cystadenocarcinoma, Serous / metabolism. Epithelium / metabolism. Female. GPI-Linked Proteins. Humans. Immunohistochemistry / methods. Ovary / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Staining and Labeling. Up-Regulation

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18331757.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA165009; United States / NCI NIH HHS / CA / R33CA103595; United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CEACAM6 protein, human; 0 / Cell Adhesion Molecules; 0 / GPI-Linked Proteins
  •  go-up   go-down


33. Ylisaukko-oja SK, Cybulski C, Lehtonen R, Kiuru M, Matyjasik J, Szymañska A, Szymañska-Pasternak J, Dyrskjot L, Butzow R, Orntoft TF, Launonen V, Lubiñski J, Aaltonen LA: Germline fumarate hydratase mutations in patients with ovarian mucinous cystadenoma. Eur J Hum Genet; 2006 Jul;14(7):880-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germline fumarate hydratase mutations in patients with ovarian mucinous cystadenoma.
  • HLRCC is characterized by benign leiomyomas of the skin and the uterus, renal cell carcinoma, and uterine leiomyosarcoma.
  • The aim of this study was to identify new families with FH mutations, and to further examine the tumor spectrum associated with FH mutations.
  • FH germline mutations were screened from 89 patients with RCC, skin leiomyomas or ovarian tumors.
  • Subsequently, 13 ovarian and 48 bladder carcinomas were analyzed for somatic FH mutations.
  • Two patients diagnosed with ovarian mucinous cystadenoma (two out of 33, 6%) were found to be FH germline mutation carriers.
  • These results suggest that benign ovarian tumors may be associated with HLRCC.
  • [MeSH-major] Cystadenoma, Mucinous / genetics. Fumarate Hydratase / genetics. Germ-Line Mutation. Neoplastic Syndromes, Hereditary / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Carcinoma, Renal Cell / genetics. Cystadenocarcinoma, Mucinous / genetics. Female. Genes, Dominant. Humans. Kidney Neoplasms / genetics. Leiomyoma / genetics. Male. Neoplasms / genetics. Skin Neoplasms / genetics. Urinary Bladder Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16639410.001).
  • [ISSN] 1018-4813
  • [Journal-full-title] European journal of human genetics : EJHG
  • [ISO-abbreviation] Eur. J. Hum. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 4.2.1.2 / Fumarate Hydratase
  •  go-up   go-down


34. Veras E, Deavers MT, Silva EG, Malpica A: Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases. Am J Surg Pathol; 2007 May;31(5):774-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases.
  • Nonsmall cell neuroendocrine carcinoma (NSCNEC) of the ovary is a rare and aggressive tumor commonly associated with other surface epithelial and germ cell neoplasms.
  • Tumors were mostly unilateral, cystic, or solid/cystic and ranged in size from 5 to 26 cm (mean 16.2).
  • In 8 cases, NSCNEC was associated with other epithelial neoplasms, including mucinous neoplasms of low malignant potential, mucinous carcinoma, endometrioid carcinoma, mixed endometrioid and mucinous carcinoma, and a high-grade carcinoma, not otherwise specified.
  • In 2 cases, the tumor was associated with a mature cystic teratoma; one of them also containing an invasive moderately differentiated adenocarcinoma.
  • A single case was associated with a benign ovarian cyst.
  • The latter case had a dermoid cyst in the contralateral ovary.
  • NSCNEC represented anywhere from 10% to 90% of the ovarian tumor.
  • All tumors had a brisk mitotic activity.
  • According to the International Federation of Gynecology and Obstetrics staging system, 4 cases were stage I tumors, 3 cases were stage III tumors, and 4 cases were stage IV tumors.
  • Four of 5 patients who died of disease had either stage III or IV tumors and 3 of 5 patients who are alive without evidence of disease have stage I tumors.
  • In summary, ovarian NSCNEC is an aggressive tumor with a tendency to present at advanced stage and cause death within a mean of 17 months after diagnosis; however, some patients, particularly those with stage I disease and/or those who have received platinum-based therapy, may have a more favorable prognosis.
  • [MeSH-major] Biomarkers, Tumor. Carcinoma, Neuroendocrine / pathology. Immunoenzyme Techniques. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Staging. Neoplasms, Multiple Primary. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460463.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


35. Tyler KL, Bell MC, Ziebarth JA: A rare case of squamous cell carcinoma arising in a mature cystic teratoma of the ovary. S D Med; 2007 Oct;60(10):401-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of squamous cell carcinoma arising in a mature cystic teratoma of the ovary.
  • Mature cystic teratoma is a common benign adnexal tumor in females.
  • We describe a 43-year-old female with a 10 cm left ovarian mature cystic teratoma with the rare finding of squamous cell carcinoma.
  • [MeSH-major] Neoplasms, Squamous Cell / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Fatal Outcome. Female. Humans. Hysterectomy. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18019775.001).
  • [ISSN] 0038-3317
  • [Journal-full-title] South Dakota medicine : the journal of the South Dakota State Medical Association
  • [ISO-abbreviation] S D Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. He Y, Yang KX, Jiang W, Wang DQ, Li L: Sclerosing stromal tumor of the ovary in a 4-year-old girl with characteristics of an ovarian signet-ring stromal tumor. Pathol Res Pract; 2010 May 15;206(5):338-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing stromal tumor of the ovary in a 4-year-old girl with characteristics of an ovarian signet-ring stromal tumor.
  • Ovarian sclerosing stromal tumor (OSST) is an extremely rare neoplasm that primarily affects young women.
  • Signet-ring stromal tumor is another rare non-functioning benign ovarian stromal neoplasm.
  • We report a case of a right OSST with prominent characteristics of signet-ring stromal tumor in a 4-year-old girl with symptoms of premature thelarche.
  • The presence of non-mucin/non-lipid obvious signet-ring-like cells in this case suggests a possible relationship between OSST and signet-ring stromal tumor of the ovary.
  • [MeSH-major] Carcinoma, Signet Ring Cell / pathology. Ovarian Neoplasms / pathology. Sex Cord-Gonadal Stromal Tumors / pathology. Stromal Cells / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Child, Preschool. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Sclerosis / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009. Published by Elsevier GmbH. All rights reserved.
  • (PMID = 19604650.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


37. Kushida Y, Haba R, Kadota K, Doi T, Ishikawa M, Hirakawa E, Kira M: Composite mucinous and granulosa cell tumor of the ovary. Pathol Int; 2005 Dec;55(12):797-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite mucinous and granulosa cell tumor of the ovary.
  • A composite mucinous and granulosa cell tumor of the ovary in a 76-year-old woman is herein reported.
  • At laparotomy this tumor proved to be a solid and cystic mass measuring 10 cm in greatest diameter.
  • Many of the cysts were lined with a benign mucinous epithelium of the endocervical type, and solid areas contained a proliferation of granulosa cells.
  • The coexistence of mucinous and granulosa cell tumor is extremely rare and only four such cases have previously been reported in the literature, and the histogenesis of this tumor has not yet been elucidated.
  • In the present case it is suggested that the granulosa cell element commenced as a reactive stromal hyperplasia in the wall of the pre-existing mucinous neoplasm and thereafter progressed to the point of producing a tumor-like mass or neoplastic changes.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Granulosa Cell Tumor / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16287496.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


38. Badiglian Filho L, Oshima CT, De Oliveira Lima F, De Oliveira Costa H, De Sousa Damião R, Gomes TS, Gonçalves WJ: Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer. Oncol Rep; 2009 Feb;21(2):313-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer.
  • In ovarian cancer, the role played by Wnts and its pathways is not clearly defined.
  • In order to analyze the canonical and noncanonical Wnt pathway in normal ovary, benign ovarian tumor and ovarian cancer, we evaluated the immunohistochemical expression of Wnt1, Frizzled-1 (FZD1), Wnt5a, Frizzled-5 (FZD5) and beta-catenin.
  • Ovarian specimens were obtained from surgeries performed between 1993 and 2004.
  • The patients were divided in three groups: group A, epithelial ovarian cancer (n=38); group B, benign epithelial neoplasia (n=28); and group C, normal ovaries (n=26).
  • Our findings suggest that the pathways related to Wnt5a have an important role in ovarian malignant neoplasia.
  • Furthermore, Wnt5a was found to be a predictor of poor prognosis for ovarian cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Frizzled Receptors / biosynthesis. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Wnt Proteins / biosynthesis. beta Catenin / biosynthesis
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Neoplasm Staging. Ovary. Prognosis. Signal Transduction / physiology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19148501.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Frizzled Receptors; 0 / Wnt Proteins; 0 / beta Catenin
  •  go-up   go-down


39. Diamantopoulou S, Sikiotis K, Panayiotides J, Kassanos D: Serous cystadenoma with massive ovarian edema. A case report and review of the literature. Clin Exp Obstet Gynecol; 2009;36(1):58-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous cystadenoma with massive ovarian edema. A case report and review of the literature.
  • BACKGROUND: Massive ovarian edema is an usual tumour-like condition.
  • It may be confused with an ovarian neoplasm.
  • Ultrasound revealed a mass of a non-echogenic cystic compartment of 13 cm maximum diameter, and an area of mixed echogenicity of 11 cm maximum diameter at the anatomic site of the right ovary.
  • The pathology examination revealed serous cystadenoma with massive ovarian edema.
  • CONCLUSIONS: Conservative treatment and ovarian suspension may be more appropriate, when histology on frozen section suggests a benign lesion.
  • [MeSH-major] Cystadenoma, Serous / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19400422.001).
  • [ISSN] 0390-6663
  • [Journal-full-title] Clinical and experimental obstetrics & gynecology
  • [ISO-abbreviation] Clin Exp Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 27
  •  go-up   go-down


40. Koensgen D, Mustea A, Klaman I, Sun P, Zafrakas M, Lichtenegger W, Denkert C, Dahl E, Sehouli J: Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression. Gynecol Oncol; 2007 Nov;107(2):266-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression.
  • OBJECTIVE: The plasminogen activator system (PA) plays an important role in invasion and metastasis of solid tumors.
  • Expression of PAI-RBP1 (the new, approved gene symbol is SERBP1) has not been previously analyzed in human tumors.
  • We present herein for the first time expression analysis of PAI-RBP1 in epithelial ovarian cancer.
  • METHODS: PAI-RBP1 was identified as gene overexpressed in ovarian cancer by an in silico approach using EST database mining.
  • A thorough expression analysis of PAI-RBP1 and PAI-1 was performed in normal ovary (n=4), benign (n=6) and malignant (n=42) ovarian lesions using non-radioactive RNA in situ hybridization and immunohistochemistry, respectively.
  • RESULTS: PAI-RBP1 mRNA and PAI-1 were significantly overexpressed in tumor epithelial cells as compared to benign and normal ovarian tissue.
  • CONCLUSION: In ovarian cancer, PAI-RBP1 is significantly overexpressed in tumor epithelial cells, suggesting a biological role in tumor invasion and metastasis.
  • Its expression is higher in advanced disease, thus the prognostic significance of PAI-RBP1 in ovarian cancer remains to be evaluated in further studies.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma / chemistry. Carcinoma / pathology. Ovarian Neoplasms / chemistry. Ovarian Neoplasms / pathology. Plasminogen Activator Inhibitor 1 / analysis. Retinol-Binding Proteins, Cellular / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Neoplasm, Residual. Predictive Value of Tests. Prognosis. RNA, Messenger / analysis. RNA, Neoplasm / analysis. Survival Analysis. Up-Regulation


41. Schröder FH: Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Can J Urol; 2005 Feb;12 Suppl 1:2-6; discussion 92-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The ERSPC together with the prostate cancer arm of the Prostate, Lung, Colon and Ovary (PLCO) screening trial of the National Cancer Institute in the United States are set to show or exclude an effect of screening on prostate cancer mortality.
  • Present screening needs to be more "selective" for cases that have aggressive patterns and are likely to lead to clinical diagnosis of prostate cancer and/or death.
  • This may be compatible with the observation that tumor volumes in second round screening are smaller, and larger tumors are harvested.
  • Tumor volume becomes a negative predictor in round 2, indicating that a large proportion of elevated PSA values are caused by benign prostatic hyperplasia (BPH) rather than by prostate cancer.
  • [MeSH-major] Mass Screening / standards. Prostate-Specific Antigen / blood. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Age Distribution. Aged. Europe / epidemiology. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Prognosis. Randomized Controlled Trials as Topic. Risk Assessment. Survival Rate. Time Factors


42. Zhang X, Wu LY, Li XJ, Li HJ, Zhang R, Liu LY: [Clinical analysis of benign pelvic mass with high serum levels of CA(125)]. Zhonghua Fu Chan Ke Za Zhi; 2005 Mar;40(3):178-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of benign pelvic mass with high serum levels of CA(125)].
  • OBJECTIVE: To investigate serum CA(125) levels and the value of serum CA(125) in differential diagnosis of benign pelvic mass.
  • METHODS: We retrospectively analyzed 492 patients with benign pelvic mass, including 237 cases of benign ovarian tumor and 255 other benign gynecological diseases.
  • Sixty cases of ovarian epithelial cancer were randomly chosen as control group.
  • RESULTS: The median of serum CA(125) in patients with pelvic tuberculosis, uterine adenomyosis, ovarian endometriosis and ovarian fibroma were all higher than the cut-off level of CA(125) (35 kU/L), being 465.0, 88.9, 59.0 and 44.5 kU/L, respectively.
  • Those of ovarian epithelial cancer patients were significantly higher than in benign pelvic mass (P < 0.01).
  • The highest value of CA(125) among all the benign cases was 1281.0 kU/L, which was seen in a case of ovarian thecoma.
  • The highest median value was 465.0 kU/L, detected in a patient with pelvic tuberculosis.
  • CONCLUSIONS: Serum CA(125) levels in some benign pelvic mass are higher than the cut-off level of CA(125), such as pelvic tuberculosis, uterine adenomyosis, ovarian fibroma and ovarian endometriosis.
  • The medians of serum CA(125) in benign pelvic mass are much lower than in ovarian epithelial cancer.
  • Serum CA(125) is of significance in the differential diagnosis between hysteromyoma and uterine adenomyosis.
  • [MeSH-major] CA-125 Antigen / blood. Membrane Proteins / blood. Ovarian Neoplasms / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Female. Humans. Middle Aged. Retrospective Studies. Tumor Burden. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15840313.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / MUC16 protein, human; 0 / Membrane Proteins
  •  go-up   go-down


43. Gadomska H, Grzechocińska B, Janecki J, Nowicka G, Powolny M, Marianowski L: Serum lipids concentration in women with benign and malignant ovarian tumours. Eur J Obstet Gynecol Reprod Biol; 2005 May 1;120(1):87-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum lipids concentration in women with benign and malignant ovarian tumours.
  • Early diagnosis can improve clinical effects of ovarian carcinoma treatment.
  • Serum lipid and lipoprotein association with neoplasm is already established.
  • In our study, we have examined concentration of total cholesterol, free cholesterol, HDL cholesterol, HDL3 and HDL free cholesterol fraction, triglycerides, and apolipoproteins: AI, AII and B and aimed to prepare the most likely model of lipid profile in women suffering from ovarian neoplasm.
  • The serum lipid parameters were analysed in 91 operated patients: 64 with ovarian malignant tumour, 27 with benign ovarian cysts and 44 apparently healthy age-matching pair women as a control group.
  • THE RESULTS: concentration of two parameters: apolipoprotein AI and free cholesterol allows for excluding ovarian neoplasm in 95.5%; examination of six parameters: apolipoprotein AI, free cholesterol, HDL-free cholesterol, HDL total cholesterol, apolipoprotein B and HDL3 fraction allows for diagnosing ovarian malignancy with 97% probability.
  • No statistically significant difference between malignant and benign ovarian tumour has been confirmed.
  • [MeSH-major] Lipids / blood. Ovarian Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15866092.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Apolipoprotein A-I; 0 / Apolipoprotein A-II; 0 / Apolipoproteins B; 0 / Cholesterol, HDL; 0 / Lipids; 0 / Lipoproteins, HDL; 0 / Lipoproteins, HDL3; 0 / Triglycerides; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


44. Fain-Kahn V, Poirot C, Uzan C, Prades M, Gouy S, Genestie C, Duvillard P, Morice P: Feasibility of ovarian cryopreservation in borderline ovarian tumours. Hum Reprod; 2009 Apr;24(4):850-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of ovarian cryopreservation in borderline ovarian tumours.
  • BACKGROUND: Borderline ovarian tumours (BOT) do not exhibit overt stromal invasion and are less aggressive than invasive epithelial ovarian tumours.
  • BOT also arise in younger patients than those who develop epithelial ovarian tumours.
  • Our aim was to evaluate the feasibility of ovarian cryopreservation (OC) in patients treated for BOT.
  • RESULTS: Twenty-three patients, treated between January 2002 and February 2008, were initially selected but six of them were excluded from the present study (four because the tumour was malignant and two because it was benign).
  • In eight cases, OC was not performed; instead, in four cases a simple cystectomy was finally performed (one patient was in fact pregnant at the time of surgery), in one case malignant disease was found and in three (18%) patients OC was not technically feasible because no normal ovarian parenchyma was evident on gross inspection.
  • In 18%, this procedure was aborted because no macroscopic healthy ovarian tissue could be found.
  • [MeSH-major] Cryopreservation / methods. Ovarian Neoplasms / surgery. Ovary
  • [MeSH-minor] Adolescent. Adult. Female. Fertility. Humans. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Pregnancy. Retrospective Studies. Transplantation, Autologous. Young Adult


45. Pragathi P, Bharath Kumar PV, Amar Kumar P, Ramakanth Reddy M, Sravani V, Neeraja J, Reeba Mary E, Gopalakrishna K: Evaluation of serum adenosine deaminase and 5'-nucleotidase activities as probable markers in ovarian cancer. Indian J Clin Biochem; 2005 Jul;20(2):195-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of serum adenosine deaminase and 5'-nucleotidase activities as probable markers in ovarian cancer.
  • Adenosine deaminase (ADA) and 5'-nucleotidase (5'-NT) activities were measured in sera of patients with ovarian cancer and patients with benign ovarian tumour.
  • ADA levels were significantly increased (P<0.001) in the ovarian cancer group (n=50) but not in the benign group (n=28) when compared to the controls (n=20).
  • The results indicate that ADA and 5'-NT levels may help to differentiate malignant conditions from benign tumours of the ovary in addition to the existing tests such as serum CA-125 levels and histopathological study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Sov Med. 1991;(2):14-7 [2057830.001]
  • [Cites] J Invest Dermatol. 1985 Mar;84(3):199-202 [3973404.001]
  • [Cites] Clin Chem. 1981 Mar;27(3):464-5 [6258823.001]
  • [Cites] Cancer Lett. 1994 Feb 28;77(1):39-43 [7512886.001]
  • [Cites] Med Oncol. 2000 Nov;17(4):319-24 [11114712.001]
  • [Cites] Clin Chim Acta. 1981 Sep;115(3):349-58 [6117383.001]
  • (PMID = 23105561.001).
  • [ISSN] 0970-1915
  • [Journal-full-title] Indian journal of clinical biochemistry : IJCB
  • [ISO-abbreviation] Indian J Clin Biochem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3453859
  • [Keywords] NOTNLM ; 5′-NT / ADA / CA-125 / Ovarian cancer
  •  go-up   go-down


46. Chauhan SC, Vinayek N, Maher DM, Bell MC, Dunham KA, Koch MD, Lio Y, Jaggi M: Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multi-targeted antibody-guided therapy. J Histochem Cytochem; 2007 Aug;55(8):867-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multi-targeted antibody-guided therapy.
  • Single antigen-targeted intraperitoneal radioimmunotherapy for ovarian cancer has shown limited success.
  • Due to the heterogeneous expression of tumor antigens on cancer cells, a multi-antigen targeting approach appears logical to augment the therapeutic efficacy of antibody-guided therapy.
  • In the interest of developing this novel approach, ovarian cancer tissue microarray slides containing cancer and benign/non-neoplastic tissue samples (n=92) were processed for single-, double-, and triple-antigen labeling using antibodies for the tumor-associated antigens TAG-72, MUC1, and CA125.
  • Among all ovarian cancer types, 72%, 61%, and 50% of the samples showed immunolabeling for TAG-72, MUC1, and CA125, respectively.
  • Of the 48 epithelial ovarian cancer samples, individual anti-TAG-72, MUC1, and CA125 antibody probing showed labeling in 89.5%, 87.5%, and 73.0% of the cases, respectively.
  • However, upon combining the three antigens (triple-antigen labeling), 98% of the epithelial ovarian cancer samples were labeled and >95% of the cancer cells within each sample were labeled.
  • Therapeutic efficacy of antibody-guided therapy for ovarian cancer treatment will be enhanced by the combined targeting of TAG-72, MUC1, and CA125.
  • [MeSH-major] Antibodies. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. CA-125 Antigen / metabolism. Glycoproteins / metabolism. Mucins / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Drug Carriers. Female. Humans. Mucin-1. Neoplasms, Glandular and Epithelial / metabolism. Ovary / metabolism. Tissue Array Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17478446.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Drug Carriers; 0 / Glycoproteins; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Mucins; 0 / tumor-associated antigen 72
  •  go-up   go-down


47. Penumatsa K, Edassery SL, Barua A, Bradaric MJ, Luborsky JL: Differential expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian tumors. J Ovarian Res; 2010;3:28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian tumors.
  • BACKGROUND: We showed there are specific ALDH1 autoantibodies in ovarian autoimmune disease and ovarian cancer, suggesting a role for ALDH1 in ovarian pathology.
  • However, there is little information on the ovarian expression of ALDH1.
  • Therefore, we compared ALDH1 expression in normal ovary and benign and malignant ovarian tumors to determine if ALDH1 expression is altered in ovarian cancer.
  • Since there is also recent interest in ALDH1 as a cancer stem cell (CSC) marker, we assessed co-expression of ALDH1 with CSC markers in order to determine if ALDH1 is a potential CSC marker in ovarian cancer.
  • METHODS: mRNA and protein expression were compared in normal human ovary and serous ovarian tumors using quantitative Reverse-Transcriptase PCR, Western blot (WB) and semi-quantitative immunohistochemistry (IHC).
  • ALDH1 enzyme activity was confirmed in primary ovarian cells by flow cytometry (FC) using ALDEFLUOR assay.
  • RESULTS: ALDH1 mRNA expression was significantly reduced (p < 0.01; n = 5) in malignant tumors compared to normal ovaries and benign tumors.
  • The proportion of ALDH1+ cells was significantly lower in malignant tumors (17.1 ± 7.61%; n = 5) compared to normal ovaries (37.4 ± 5.4%; p < 0.01; n = 5) and benign tumors (31.03 ± 6.68%; p < 0.05; n = 5).
  • ALDH1+ cells occurred in the stroma and surface epithelium in normal ovary and benign tumors, although surface epithelial expression varied more in benign tumors.
  • Localization of ALDH1 was heterogeneous in malignant tumor cells and little ALDH1 expression occurred in poorly differentiated malignant tumors.
  • In benign tumors the distribution of ALDH1 had features of both normal ovary and malignant tumors.
  • CONCLUSIONS: Total ALDH1 expression is significantly reduced in malignant ovarian tumors while it is relatively unchanged in benign tumors compared to normal ovary.
  • Thus, ALDH1 expression in the ovary does not appear to be similar to breast, lung or colon cancer suggesting possible functional differences in these cancers.
  • SIGNIFICANCE: These observations suggest that reduced ALDH1 expression is associated with malignant transformation in ovarian cancer and provides a basis for further study of the mechanism of ALDH1 in this process.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Immunol. 2009 Feb;21(1):22-7 [18778953.001]
  • [Cites] Mol Cancer. 2008;7:87 [19025616.001]
  • [Cites] Cell Cycle. 2009 Jan 1;8(1):158-66 [19158483.001]
  • [Cites] Br J Cancer. 2009 Apr 7;100(7):1144-53 [19293794.001]
  • [Cites] Fertil Steril. 2010 Dec;94(7):2636-41 [20522323.001]
  • [Cites] Int J Cancer. 1994 Mar 1;56(5):743-8 [8314353.001]
  • [Cites] J Cell Physiol. 2000 Oct;185(1):1-20 [10942515.001]
  • [Cites] Endocrinology. 2000 Oct;141(10):3638-45 [11014218.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6744-9 [11118061.001]
  • [Cites] Annu Rev Nutr. 2002;22:347-81 [12055350.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Chem Biol Interact. 2003 Feb 1;143-144:201-10 [12604205.001]
  • [Cites] J Biochem Mol Toxicol. 2003;17(1):7-23 [12616643.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1013-20 [12631600.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1648-55 [15178579.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3025-9 [15833827.001]
  • [Cites] FASEB J. 1991 Nov;5(14):2924-33 [1661245.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):1092-100 [16969345.001]
  • [Cites] J Immunol. 2007 Sep 15;179(6):3724-33 [17785809.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10538-45 [17974998.001]
  • [Cites] J Cell Sci. 1991 Nov;100 ( Pt 3):657-66 [1808213.001]
  • [Cites] Cell Stem Cell. 2007 Nov;1(5):555-67 [18371393.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4311-20 [18519691.001]
  • [Cites] Mol Cancer Res. 2008 Jul;6(7):1146-53 [18644979.001]
  • [Cites] J Cell Mol Med. 2009 Aug;13(8B):2236-52 [18681906.001]
  • [Cites] Int Immunol. 2009 Apr;21(4):361-77 [19190084.001]
  • [Cites] Mol Cancer Res. 2009 Mar;7(3):330-8 [19276181.001]
  • [Cites] Birth Defects Res C Embryo Today. 2009 Mar;87(1):64-89 [19306350.001]
  • [Cites] Mod Pathol. 2009 Jun;22(6):817-23 [19329942.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3382-9 [19336570.001]
  • [Cites] Nucl Recept Signal. 2009;7:e002 [19381305.001]
  • [Cites] Stem Cells. 2009 Dec;27(12):2875-83 [19816957.001]
  • [Cites] Breast Cancer Res Treat. 2010 Aug;123(1):109-11 [19946740.001]
  • [Cites] Lab Invest. 2010 Feb;90(2):234-44 [20010854.001]
  • [Cites] Clin Cancer Res. 2010 Feb 1;16(3):876-87 [20103682.001]
  • [Cites] PLoS One. 2010;5(4):e10277 [20422001.001]
  • [Cites] Cell Commun Signal. 2010;8(1):6 [20459772.001]
  • [Cites] J Microsc. 1987 Sep;147(Pt 3):229-63 [3430576.001]
  • [Cites] J Natl Cancer Inst. 1995 Jan 18;87(2):146-7 [7707390.001]
  • [Cites] Neurobiol Aging. 1993 Jul-Aug;14(4):275-85 [8367009.001]
  • [Cites] Clin Immunol Immunopathol. 1996 Sep;80(3 Pt 2):S52-62 [8811064.001]
  • [Cites] Gynecol Oncol. 1997 Apr;65(1):54-62 [9103391.001]
  • [Cites] Clin Cancer Res. 1997 Nov;3(11):2033-8 [9815594.001]
  • [Cites] J Investig Med. 1996 Feb;44(2):42-6 [8689400.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2157-63 [12727970.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):14-25 [15305371.001]
  • [Cites] Mol Cancer. 2004 Oct 7;3:27 [15471544.001]
  • [Cites] J Endocrinol. 2004 Oct;183(1):19-28 [15525570.001]
  • [Cites] Hum Genomics. 2005 Jun;2(2):138-43 [16004729.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11707-12 [16857736.001]
  • [Cites] Cytometry B Clin Cytom. 2007 Jul;72(4):281-9 [17111384.001]
  • [Cites] Lung Cancer. 2008 Mar;59(3):340-9 [17920722.001]
  • [Cites] Toxicol Sci. 2008 Jan;101(1):51-64 [17998271.001]
  • [Cites] Endocrinology. 2008 Sep;149(9):4307-11 [18556344.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2008 Jun;4(6):697-720 [18611112.001]
  • (PMID = 21176222.001).
  • [ISSN] 1757-2215
  • [Journal-full-title] Journal of ovarian research
  • [ISO-abbreviation] J Ovarian Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3022900
  •  go-up   go-down


48. Osterberg L, Akeson M, Levan K, Partheen K, Zetterqvist BM, Brännström M, Horvath G: Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas. Cancer Genet Cytogenet; 2006 Jun;167(2):103-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas.
  • Borderline tumors of the ovary comprise 10-20% of all epithelial ovarian tumors, and are placed between clearly benign and obviously malignant ovarian tumors.
  • The issue of whether borderline tumors are precursors of invasive carcinoma or distinct clinical entities, however, is still the subject of discussion.
  • To increase our understanding in relation to this issue, the aim of our study was to analyze both serous borderline and invasive ovarian tumors, and to investigate early carcinogenesis in serous ovarian tumors.
  • Using comparative genomic hybridization, we compared cytogenetic changes in borderline ovarian tumors and stage I invasive tumors.
  • The average number of genetic alterations differed significantly between the borderline and the invasive tumors (1.9 and 9.2, respectively).
  • The most common genetic alterations among the borderline tumors were loss of chromosome 17, 20q, and 18p, and gain of 12p13 approximately q23.
  • These changes were also found among the invasive tumors in a similar percentage.
  • In conclusion, we found four distinct cytogenetic alterations that might be early events in serous ovarian tumors, and that might also characterize a subgroup of borderline ovarian tumors that may have the potential to progress and develop malignancy.
  • [MeSH-major] Aneuploidy. Carcinoma / genetics. Ovarian Neoplasms / genetics. Serous Membrane
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. DNA, Neoplasm / analysis. Female. Humans. Middle Aged. Neoplasm Staging. Nucleic Acid Hybridization

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16737908.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


49. Briones-Landa CH, Ayala-Yáñez R, Leroy-López L, Anaya-Coeto H, Santarosa-Pérez MA, Reyes-Muñoz E: [Comparison of laparoscopic vs. laparotomy treatment in ovarian teratomas]. Ginecol Obstet Mex; 2010 Oct;78(10):527-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of laparoscopic vs. laparotomy treatment in ovarian teratomas].
  • [Transliterated title] Comparación del tratamiento laparoscópico vs laparotomía en teratomas ováricos.
  • BACKGROUND: Benign cystic teratoma is one of the most common benign tumors of the ovary, according to international series represents between 44 and 62% of all ovarian tumors diagnosed in women younger than 40 years.
  • OBJECTIVES: To evaluate and compare the efficacy and safety between laparoscopy and laparotomy in the management of ovarian teratomas, as well as the recurrence between both techniques.
  • MATERIALS AND METHOD: Retrospective, clinical series study involving 169 cases of ovarian teratomas operated at the Instituto Nacional de Perinatología Isidro Espinosa de los Reyes in the period comprehended between 2000-2008.
  • Laparoscopy was a risk factor for broken open for ovarian cyst (OR: 6.9; CI 95%: 3.3-14.8).
  • [MeSH-major] Laparoscopy. Laparotomy. Ovarian Neoplasms / surgery. Teratoma / surgery
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Blood Loss, Surgical. CA-125 Antigen / blood. Dermoid Cyst / blood. Dermoid Cyst / surgery. Dermoid Cyst / ultrasonography. Female. Humans. Intraoperative Complications / etiology. Length of Stay / statistics & numerical data. Ovarian Cysts / blood. Ovarian Cysts / surgery. Ovarian Cysts / ultrasonography. Postoperative Complications / epidemiology. Predictive Value of Tests. Retrospective Studies. Rupture / etiology. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21966769.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


50. Chang WC, Sheu BC, Lin MC, Chow SN, Huang SC: Carcinosarcoma-like mural nodule in intestinal-type mucinous ovarian of borderline malignancy: a case report. Int J Gynecol Cancer; 2005 May-Jun;15(3):549-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinosarcoma-like mural nodule in intestinal-type mucinous ovarian of borderline malignancy: a case report.
  • Epithelial ovarian tumors of borderline malignancy are tumors with histologic features and biologic behavior between benign and frankly malignant epithelial ovarian neoplasms.
  • Here, we present a 35-year-old patient with carcinosarcoma-like mural nodule in intestinal-type mucinous ovarian tumor of borderline malignancy.
  • Total hysterectomy, bilateral salpingo-oophorectomy, appendectomy, and omentectomy were performed, and the frozen pathology during operation showed mucinous tumor of borderline malignancy of left ovary on April 18, 2002.
  • It is difficult to determine whether intestinal-type borderline mucinous tumors with intraepithelial carcinoma are associated with a worse prognosis compared with those with epithelial atypia alone due to disparate results in the published literature.
  • However, too few cases of carcinosarcoma-like mural nodule in mucinous tumor have been published to warrant a conclusion regarding their prognosis.
  • [MeSH-major] Carcinosarcoma / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Neoplasm Invasiveness. Prognosis

  • Genetic Alliance. consumer health - Ovarian carcinosarcoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15882184.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Gupta N, Bisht D, Agarwal AK, Sharma VK: Retrospective and prospective study of ovarian tumours and tumour-like lesions. Indian J Pathol Microbiol; 2007 Jul;50(3):525-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective and prospective study of ovarian tumours and tumour-like lesions.
  • Two hundred and thirty three cases of ovarian tumours and tumour like lesions were studied.
  • Of these 233 cases, 96 cases were of ovarian tumours and 137 were tumour like lesions of the ovary.
  • Of the 96 cases of ovarian tumours, 72.9% were benign, 4.1% were borderline and 22.9% were malignant.
  • Ultrasound guided FNAC done in cases of ovarian tumours showed an accuracy of 100% for malignant lesions and 100% for benign and borderline lesions when compared with histopathological diagnosis.
  • Tuberculosis constituted (2.9%) cases and was the major cause of clinical diagnostic pitfalls for cases in which a clinical diagnosis of ovarian neoplasm was made.
  • [MeSH-major] Ovarian Diseases. Ovarian Neoplasms. Peritonitis, Tuberculous
  • [MeSH-minor] Female. Humans. Incidence. Neoplasms, Germ Cell and Embryonal / epidemiology. Neoplasms, Germ Cell and Embryonal / pathology. Ovary / pathology. Prospective Studies. Retrospective Studies. Sex Cord-Gonadal Stromal Tumors / epidemiology. Sex Cord-Gonadal Stromal Tumors / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883123.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


52. Yazbek J, Aslam N, Tailor A, Hillaby K, Raju KS, Jurkovic D: A comparative study of the risk of malignancy index and the ovarian crescent sign for the diagnosis of invasive ovarian cancer. Ultrasound Obstet Gynecol; 2006 Sep;28(3):320-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparative study of the risk of malignancy index and the ovarian crescent sign for the diagnosis of invasive ovarian cancer.
  • OBJECTIVE: To compare the value of the risk of malignancy index (RMI) and the ovarian crescent sign (OCS) in the diagnosis of ovarian malignancy.
  • METHODS: This was a prospective observational study of women with ultrasonographic diagnosis of an ovarian cyst.
  • The RMI was calculated in all cases using a previously published formula (RMI = U (ultrasound score) x M (menopausal status) x serum CA125 (kU/L)).
  • A value > 200 was considered to be diagnostic of ovarian cancer.
  • The OCS was defined as a rim of visible healthy ovarian tissue in the ipsilateral ovary.
  • RESULTS: A total of 106 consecutive women were included in the study, of whom 92 (86.8%) had a benign ovarian tumor, five (4.7%) had borderline lesions and nine (8.5%) had an invasive ovarian cancer.
  • The absence of an OCS diagnosed invasive ovarian cancer with a sensitivity of 100% (95% CI, 70-100%), specificity of 93% (95% CI, 86-96%), positive predictive value (PPV) of 56%, negative predictive value (NPV) of 100% and positive likelihood ratio (LR+) of 13.86 (95% CI, 6.79-28.29).
  • CONCLUSIONS: The RMI and the OCS are useful tests for discriminating between invasive and non-invasive ovarian tumors.
  • The application of these tests in a sequential manner might improve the overall accuracy of ovarian cancer diagnosis.
  • [MeSH-major] Ovarian Neoplasms / ultrasonography. Ovary / ultrasonography. Severity of Illness Index
  • [MeSH-minor] Algorithms. CA-125 Antigen / blood. Diagnosis, Differential. False Positive Reactions. Female. Humans. Middle Aged. Ovarian Cysts / surgery. Ovarian Cysts / ultrasonography. Predictive Value of Tests. Prospective Studies. ROC Curve. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 ISUOG. Published by John Wiley & Sons, Ltd.
  • (PMID = 16881074.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


53. Kim JY, Lee YC, Kim C: Direct inhibition of Pumilo activity by Bam and Bgcn in Drosophila germ line stem cell differentiation. J Biol Chem; 2010 Feb 12;285(7):4741-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The RNA-binding translational repressor Pumilio (Pum) in conjunction with Nanos (Nos) is required for self-renewal, whereas Bam (bag-of-marbles) and Bgcn (benign gonial cell neoplasm) promote differentiation of germ line stem cells in the Drosophila ovary.
  • Notably, the N-terminal region of Pum, which lacks the C-terminal RNA-binding Puf domain, mediates both the ternary protein interaction and the Bam inhibition of Pum function.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • FlyBase. FlyBase .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. The Antibody Registry: Reagent: Antibodies .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 1999 Oct 15;13(20):2704-12 [10541556.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jul 14;106(28):11623-8 [19556547.001]
  • [Cites] Development. 2000 Dec;127(23):5225-32 [11060247.001]
  • [Cites] Science. 2002 Jun 7;296(5574):1855-7 [12052957.001]
  • [Cites] Nat Rev Genet. 2002 Dec;3(12):931-40 [12459723.001]
  • [Cites] Curr Biol. 2003 Oct 14;13(20):1786-91 [14561403.001]
  • [Cites] Development. 2003 Dec;130(26):6625-34 [14660550.001]
  • [Cites] Development. 2004 Mar;131(6):1353-64 [14973291.001]
  • [Cites] Science. 2004 Mar 26;303(5666):2016-9 [14976263.001]
  • [Cites] Curr Biol. 2004 Jun 8;14(11):981-6 [15182671.001]
  • [Cites] J Bacteriol. 1983 Jan;153(1):163-8 [6336730.001]
  • [Cites] Anal Biochem. 1988 Jun;171(2):404-8 [3407940.001]
  • [Cites] Genetics. 1989 May;122(1):19-27 [2659436.001]
  • [Cites] Genes Dev. 1990 Dec;4(12B):2242-51 [2279698.001]
  • [Cites] Cell. 1991 Nov 29;67(5):955-67 [1720354.001]
  • [Cites] Development. 1992 Jan;114(1):221-32 [1576962.001]
  • [Cites] Cell. 1993 Nov 19;75(4):791-803 [8242750.001]
  • [Cites] Dev Dyn. 1994 Feb;199(2):103-15 [7515724.001]
  • [Cites] Cell. 1995 Mar 10;80(5):747-56 [7889568.001]
  • [Cites] Development. 1995 Sep;121(9):2937-47 [7555720.001]
  • [Cites] Development. 1997 Jun;124(12):2463-76 [9199372.001]
  • [Cites] Development. 1997 Sep;124(18):3651-62 [9342057.001]
  • [Cites] RNA. 1997 Dec;3(12):1421-33 [9404893.001]
  • [Cites] Development. 1998 Feb;125(4):679-90 [9435288.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1997;62:25-34 [9598333.001]
  • [Cites] Mol Cell. 1998 May;1(6):863-72 [9660969.001]
  • [Cites] Cell. 1998 Jul 24;94(2):251-60 [9695953.001]
  • [Cites] Dev Biol. 1999 Aug 15;212(2):405-13 [10433830.001]
  • [Cites] Genetics. 1999 Sep;153(1):235-50 [10471709.001]
  • [Cites] J Biol Chem. 1999 Oct 1;274(40):28491-6 [10497212.001]
  • [Cites] Curr Biol. 2005 Jan 26;15(2):171-8 [15668175.001]
  • [Cites] Curr Biol. 2005 Jan 26;15(2):179-84 [15668176.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Jun;7(6):449-56 [16625152.001]
  • [Cites] Cell Res. 2007 Jan;17(1):15-25 [17199109.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):1925-30 [18272501.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9304-9 [19470484.001]
  • [Cites] Genetics. 2000 Aug;155(4):1809-19 [10924476.001]
  • (PMID = 20018853.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drosophila Proteins; 0 / RNA-Binding Proteins; 0 / bam protein, Drosophila; 0 / pumilio protein, Drosophila; EC 3.6.4.- / DNA Helicases; EC 3.6.4.13 / bgcn protein, Drosophila
  • [Other-IDs] NLM/ PMC2836079
  •  go-up   go-down


54. Lou YH, Yang XS, Wang FL, Qian JH, Huang Y: [Expression of microRNA-21 in ovarian epithelial carcinoma and its clinical significance]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar;30(3):608-10, 613
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of microRNA-21 in ovarian epithelial carcinoma and its clinical significance].
  • OBJECTIVE: To investigate the expression of microRNA-21(miR-21) in ovarian epithelial carcinoma and its association with the clinicopathological features.
  • METHODS: The expression of miR-21 was detected by Stem-loop real-time RT-PCR in 48 cases of ovarian epithelial carcinomas, 24 cases of benign ovarian epithelial tumors and 15 cases of normal ovarian tissues.
  • RESULTS: The relative expression level of miR-21(2-(DeltaDelta)CT) was 4.849-/+1.813 in the ovarian epithelial carcinomas, significantly higher than that in the benign ovarian tumors and normal ovarian tissues (P<0.01), but comparable between the latter two groups.
  • CONCLUSION: MiR-21 might play a role as an oncogene in the tumorigenesis and development of ovarian epithelial carcinoma, and is possibly correlated to the progression and prognosis of ovarian epithelial carcinoma.
  • [MeSH-major] Cystadenocarcinoma, Serous / genetics. MicroRNAs / metabolism. Ovarian Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20335152.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / MIRN21 microRNA, human; 0 / MicroRNAs
  •  go-up   go-down


55. Rim SY, Kim SM, Choi HS: Struma ovarii showing clinical characteristics of ovarian malignancy. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1156-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Struma ovarii showing clinical characteristics of ovarian malignancy.
  • Struma ovarii is a rare form of ovarian neoplasm, composed entirely or predominantly of thyroid tissue and generally a benign germ cell tumor of the ovary.
  • We experienced a rare case of a postmenopausal woman with benign struma ovarii associated with massive ascites, a complex pelvic mass.
  • The clinical impression was ovarian malignancy.
  • Surgical excision of the ovarian mass induced immediate resolution of the ascites and a normalization of the serum CA125 level.
  • No recurrence of the ascites or of the tumor has been observed during the 10-month follow-up.
  • Struma ovarii can mimic ovarian malignancy clinically, particularly if complex and associated with ascites and an elevated CA125 level.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Ovarian Neoplasms / pathology. Struma Ovarii / pathology. Teratoma / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343201.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


56. Tamai K, Koyama T, Saga T, Kido A, Kataoka M, Umeoka S, Fujii S, Togashi K: MR features of physiologic and benign conditions of the ovary. Eur Radiol; 2006 Dec;16(12):2700-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR features of physiologic and benign conditions of the ovary.
  • In reproductive women, various physiologic conditions can cause morphologic changes of the ovary, resembling pathologic conditions.
  • Benign ovarian diseases can also simulate malignancies.
  • Magnetic resonance imaging (MRI) can play an important role in establishing accurate diagnosis.
  • Functional cysts should not be confused with cystic neoplasms.
  • Multicystic lesions that may mimic cystic neoplasms include hyperreactio luteinalis, ovarian hyperstimulation syndrome, and polycystic ovary syndrome.
  • Recognition of clinical settings can help establish diagnosis.
  • In endometrial cysts, MRI usually provides specific diagnosis; however, decidual change during pregnancy should not be confused with secondary neoplasm.
  • Peritoneal inclusion cysts can be distinguished from cystic neoplasms by recognition of their characteristic configurations.
  • Ovarian torsion and massive ovarian edema may mimic solid malignant tumors.
  • In pelvic inflammatory diseases, transfascial spread of the lesion should not be confused with invasive malignant tumors.
  • Many benign tumors, including teratoma, Brenner tumor, and sex-cord stromal tumor, frequently show characteristic MRI features.
  • Knowledge of MRI features of these conditions is essential in establishing accurate diagnosis and determining appropriate treatment.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Ovarian Diseases / diagnosis. Ovary / anatomy & histology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Radiol. 1999 Oct;72(862):1006-11 [10673954.001]
  • [Cites] J Comput Assist Tomogr. 2000 Jan-Feb;24(1):72-6 [10667663.001]
  • [Cites] J Comput Assist Tomogr. 1999 Jul-Aug;23(4):555-7 [10433285.001]
  • [Cites] J Magn Reson Imaging. 2004 Sep;20(3):451-62 [15332253.001]
  • [Cites] Eur Radiol. 2001;11(7):1151-4 [11471603.001]
  • [Cites] Radiology. 1993 Feb;186(2):489-94 [8421756.001]
  • [Cites] Hum Reprod. 2001 Jun;16(6):1261-3 [11387302.001]
  • [Cites] Obstet Gynecol. 1977 Jul;50(1):120-8 [195239.001]
  • [Cites] Magn Reson Imaging. 1998 Dec;16(10):1147-53 [9858270.001]
  • [Cites] Eur Radiol. 1999;9(7):1335-8 [10460370.001]
  • [Cites] J Clin Ultrasound. 1981 Jul-Aug;9(6):275-80 [6454699.001]
  • [Cites] J Comput Assist Tomogr. 2001 Mar-Apr;25(2):201-6 [11242213.001]
  • [Cites] Radiology. 1991 Jul;180(1):73-8 [2052726.001]
  • [Cites] J Comput Assist Tomogr. 1990 Sep-Oct;14 (5):833-4 [2398172.001]
  • [Cites] Gynecol Oncol. 2003 Dec;91(3):648-50 [14675693.001]
  • [Cites] Gynecol Oncol. 2004 Jul;94(1):223-5 [15262147.001]
  • [Cites] AJR Am J Roentgenol. 2000 Jun;174(6):1559-63 [10845480.001]
  • [Cites] Radiology. 1996 Dec;201(3):751-5 [8939226.001]
  • [Cites] Radiographics. 2004 Oct;24 Suppl 1:S147-66 [15486238.001]
  • [Cites] Radiographics. 2002 Mar-Apr;22(2):283-94 [11896219.001]
  • [Cites] Radiographics. 2004 Nov-Dec;24(6):1575-89 [15537966.001]
  • [Cites] J Thorac Imaging. 2003 Apr;18(2):100-3 [12700485.001]
  • [Cites] AJR Am J Roentgenol. 2000 Aug;175(2):353-8 [10915674.001]
  • [Cites] J Comput Assist Tomogr. 1993 May-Jun;17 (3):477-9 [8491915.001]
  • [Cites] Eur Radiol. 2000;10(12):1954-7 [11305578.001]
  • [Cites] Radiology. 1996 Feb;198(2):397-402 [8596839.001]
  • [Cites] Korean J Radiol. 2005 Jan-Mar;6(1):44-6 [15782020.001]
  • [Cites] J Magn Reson Imaging. 1998 Nov-Dec;8(6):1203-6 [9848729.001]
  • [Cites] Eur Radiol. 2004 May;14 (5):798-804 [14504904.001]
  • [Cites] Radiographics. 2001 Mar-Apr;21(2):475-90 [11259710.001]
  • [Cites] AJR Am J Roentgenol. 2003 May;180(5):1288-90 [12704039.001]
  • [Cites] Radiographics. 2005 Jan-Feb;25(1):69-85 [15653588.001]
  • [Cites] Radiology. 1999 Jan;210(1):209-16 [9885610.001]
  • [Cites] Magn Reson Imaging. 2002 Apr;20(3):301-4 [12117613.001]
  • [Cites] AJR Am J Roentgenol. 1999 Feb;172(2):445-9 [9930800.001]
  • [Cites] AJR Am J Roentgenol. 1994 Sep;163(3):613-6 [8079854.001]
  • [Cites] Hum Reprod. 2002 Sep;17(9):2219-27 [12202405.001]
  • [Cites] Int J Gynecol Pathol. 1984;3(2):153-78 [6490313.001]
  • [Cites] AJR Am J Roentgenol. 2000 Nov;175(5):1423-30 [11044056.001]
  • [Cites] Top Magn Reson Imaging. 2001 Apr;12(2):131-46 [11296805.001]
  • [Cites] Radiology. 1996 Nov;201(2):549-52 [8888256.001]
  • [Cites] Radiol Clin North Am. 2003 Jul;41(4):799-811 [12899493.001]
  • (PMID = 16736136.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 44
  •  go-up   go-down


57. Henic E, Borgfeldt C, Christensen IJ, Casslén B, Høyer-Hansen G: Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. Clin Cancer Res; 2008 Sep 15;14(18):5785-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer.
  • PURPOSE: To evaluate the plasma level of different forms of soluble urokinase plasminogen activator receptor (suPAR) as discriminators between malignant, borderline, and benign ovarian tumors and as prognostic markers in patients with ovarian cancer.
  • Tumors were classified as benign (n = 211), borderline (possibly malignant; n = 30), and well (n = 19), moderately (n = 15), and poorly (n = 60) differentiated malignant.
  • RESULTS: All uPAR forms as well as CA125 were statistically significant in univariate analysis discriminating between benign, borderline, and invasive tumors.
  • Restricting the analysis of invasive tumors to early stage (I and II) showed similar results.
  • A combination of CA125 and suPAR(I-III) + suPAR(II-III) discriminated between malignant (all stages) and benign tumors [AUC, 0.94; 95% confidence interval (95% CI), 0.90-0.98] as well as borderline and benign tumors (AUC, 0.78; 95% CI, 0.67-0.89).
  • CONCLUSIONS: High concentration of plasma uPAR(I) is an independent preoperative marker of poor prognosis in patients with ovarian cancer.
  • The combination of plasma suPAR(I-III) + suPAR(II-III) and CA125 discriminates between malignant and benign tumors with an AUC of 0.94.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Receptors, Cell Surface / blood
  • [MeSH-minor] Biomarkers, Tumor / blood. CA-125 Antigen / analysis. Female. Humans. Prognosis. Receptors, Urokinase Plasminogen Activator

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2008 Sep 15;14(18):5643-5 [18794069.001]
  • (PMID = 18794088.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / PLAUR protein, human; 0 / Receptors, Cell Surface; 0 / Receptors, Urokinase Plasminogen Activator
  •  go-up   go-down


58. Olsen CM, Cnossen J, Green AC, Webb PM: Comparison of symptoms and presentation of women with benign, low malignant potential and invasive ovarian tumors. Eur J Gynaecol Oncol; 2007;28(5):376-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of symptoms and presentation of women with benign, low malignant potential and invasive ovarian tumors.
  • OBJECTIVES: To describe symptoms, delay in presentation and reasons for non-presentation among women diagnosed with benign, low malignant potential and malignant ovarian tumors.
  • METHODS: Study participants included 457 women who underwent surgery for an ovarian tumor in Queensland, Australia, between July 1999 and February 2002 (244 with invasive cancer, 62 with low malignant potential tumors, and 151 with benign ovarian tumors).
  • Women were contacted a minimum of three months post-diagnosis.
  • RESULTS: Overall, only 8% of the women were asymptomatic at the time of their diagnosis.
  • Women with invasive cancer reported a greater number of symptoms (3.1 and 3.6 for Stages I-II and III-IV, respectively) than women with benign or low malignant potential tumors (2.8 and 2.2 respectively; p < 0.0001).
  • Women with invasive disease were more likely to experience weight loss or gain, general malaise, chest/respiratory pain, abdominal swelling and bowel symptoms than women with benign ovarian tumors, however the symptom pattern for early- and late-stage invasive ovarian cancer could not be clearly differentiated.
  • Delay in presentation was not associated with more advanced disease suggesting that earlier diagnosis may not increase the proportion of cancers diagnosed at an early stage.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Time Factors. Weight Loss

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17966216.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


59. Shao SL, Cai Y, Wang QH, Yan LJ, Zhao XY, Wang LX: [Expression of GLUT-1, p63 and DNA-Pkcs in serous ovarian tumors and their significance]. Zhonghua Zhong Liu Za Zhi; 2007 Sep;29(9):697-700
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of GLUT-1, p63 and DNA-Pkcs in serous ovarian tumors and their significance].
  • OBJECTIVE: To investigate the expression of GLUT1, p63 and DNA-Pkcs in serous ovarian tumors and their significance.
  • METHODS: GTUL1, p63 and DNA-Pkcs expression at protein level was detected by immunohistochemistry in patients with serous ovarian tumors.
  • Chi-square analysis was used to assess if their expression is associated with clinicopathologic characteristics of the tumors.
  • RESULTS: Cells in the normal ovarian tissues were not stained with GTUL1 and p63 antiserum, but DNA-Pkcs was positively stained.
  • The intensity of GTUT1 and p63 expression was stronger in malignant ovarian serous tumors compared with other subtypes (P < 0.01).
  • There were significant differences of DNA-PKcs among normal ovaries (100.0%), benign (95.0%), borderline (90.0%) and malignant (60.0%) serious ovarian neoplasms (P < 0.01).
  • CONCLUSION: The results suggest that the abnormal expression of GTUT1, p63 and DNA-Pkcs may perhaps participate in serous ovarian tumor occurrence and development and may be considered as a marker reflecting tumor malignant behavior.
  • [MeSH-major] Cystadenocarcinoma, Serous / metabolism. DNA-Activated Protein Kinase / metabolism. Glucose Transporter Type 1 / metabolism. Nuclear Proteins / metabolism. Ovarian Neoplasms / metabolism. Trans-Activators / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Epithelium / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Ovary / cytology. Transcription Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18246802.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / Nuclear Proteins; 0 / SLC2A1 protein, human; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / DNA-Activated Protein Kinase; EC 2.7.11.1 / PRKDC protein, human
  •  go-up   go-down


60. Zhang S, Zhou X, Yu H, Yu Y: Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines. BMC Cancer; 2010;10:163
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines.
  • BACKGROUND: To observe mRNA expression of tumor-specific antigen MAGE, BAGE and GAGE in epithelial ovarian cancer tissues and cell lines, to explore the relationship between gene expression and diagnosis, treatment and prognosis of ovarian cancer, and to evaluate the feasibility of their gene products as markers, and an immunotherapy target for ovarian cancer.
  • METHODS: mRNA expression of MAGE-1, MAGE-3, GAGE-1/2 and BAGE were determined by reverse transcription polymerase chain reaction (RT-PCR) in 14 cases of normal ovarian tissue, 20 cases of ovarian benign tumor specimens, 41 cases of ovarian cancer specimens, and ovarian cancer cell lines SKOV3, A2780, and COC1.
  • RESULTS: MAGE, GAGE and BAGE genes were not expressed in normal ovarian tissue.
  • In benign tumors, only the MAGE gene was expressed; the expression rate of this gene in benign tumors was 15% (3/20).
  • In ovarian cancer tissues, MAGE-1 and MAGE-3 was highly expressed, with expression rates of 53.7% (22/41) and 36.6% (15/41), while GAGE-1/2 and BAGE had relatively low expression, with rates of 26.8% (11/41) and 14.6% (6/41).
  • In metastatic lesions of ovarian cancer, only MAGE-1 and BAGE were expressed, with expression rates of 28.6% (2/7) and 14.3% (1/7).
  • The positive expression rates of MAGE-1 and MAGE-3 in serous cystadenocarcinoma were significantly higher than that in other types of ovarian cancer (P < 0.05).
  • Positive expression of MAGE-1 and MAGE-3 was positively correlated with tumor differentiation and the clinical stage of the ovarian cancer.
  • In addition, the positive expression rate of BAGE was significantly higher in ovarian cancer patients with ascites (P < 0.05).
  • The mRNA expression profiles of MAGE, GAGE and BAGE in ovarian carcinoma cell lines SKOV3, A2780 and COC1 varied, but there was at least one gene expressed in each cell line.
  • CONCLUSION: Tumor-specific antigen MAGE, BAGE and GAGE may play a role in the occurrence and development of ovarian cancer.
  • These genes can be used as one of the important indicators for early diagnosis, efficacy evaluation and prognostic determination of ovarian cancer.
  • [MeSH-major] Antigens, Neoplasm / genetics. Biomarkers, Tumor / genetics. Cystadenocarcinoma, Serous / genetics. Neoplasm Proteins / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Cell Line, Tumor. Feasibility Studies. Female. Gene Expression Regulation, Neoplastic. Humans. Melanoma-Specific Antigens. Neoplasm Staging. Prognosis. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tissue Antigens. 2000 Aug;56(2):166-9 [11019919.001]
  • [Cites] Cancer. 2002 Jun 25;96(3):187-93 [12115308.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Aug;17(4):1051-73 [12959191.001]
  • [Cites] Int J Cancer. 1996 Jul 29;67(3):457-60 [8707425.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3931-40 [18483279.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):615-25 [16034368.001]
  • [Cites] J Clin Oncol. 2005 Dec 10;23(35):9008-21 [16061912.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1650-5 [18216244.001]
  • [Cites] J Immunol. 2008 Mar 1;180(5):3585-93 [18292586.001]
  • [Cites] Br J Cancer. 1998 Sep;78(6):816-21 [9743307.001]
  • (PMID = 20423514.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / BAGE protein, human; 0 / Biomarkers, Tumor; 0 / GAGE1 protein, human; 0 / GAGE2A protein, human; 0 / MAGEA1 protein, human; 0 / MAGEA3 protein, human; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2868811
  •  go-up   go-down


61. Van Calster B, Valentin L, Van Holsbeke C, Testa AC, Bourne T, Van Huffel S, Timmerman D: Polytomous diagnosis of ovarian tumors as benign, borderline, primary invasive or metastatic: development and validation of standard and kernel-based risk prediction models. BMC Med Res Methodol; 2010;10:96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polytomous diagnosis of ovarian tumors as benign, borderline, primary invasive or metastatic: development and validation of standard and kernel-based risk prediction models.
  • BACKGROUND: Hitherto, risk prediction models for preoperative ultrasound-based diagnosis of ovarian tumors were dichotomous (benign versus malignant).
  • We develop and validate polytomous models (models that predict more than two events) to diagnose ovarian tumors as benign, borderline, primary invasive or metastatic invasive.
  • However, discrimination between primary and metastatic invasive tumors decreased to near random levels.
  • CONCLUSIONS: We have developed models that successfully discriminate between benign, borderline, and invasive ovarian tumors.
  • The random discrimination between primary and metastatic invasive tumors on temporal/external validation demonstrated once more the necessity of validation studies.
  • [MeSH-major] Algorithms. Models, Statistical. Ovarian Neoplasms / ultrasonography. Risk Assessment / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):162-7 [11161854.001]
  • [Cites] Ultrasound Obstet Gynecol. 2010 Aug;36(2):226-34 [20455203.001]
  • [Cites] Neural Comput. 2002 May;14(5):1115-47 [11972910.001]
  • [Cites] Oncology. 2003;65(1):29-36 [12837980.001]
  • [Cites] Stat Med. 2000 Apr 30;19(8):1059-79 [10790680.001]
  • [Cites] Med Decis Making. 2001 Jan-Feb;21(1):45-56 [11206946.001]
  • [Cites] Lancet. 2001 Jan 20;357(9251):176-82 [11213094.001]
  • [Cites] Med Decis Making. 1999 Jan-Mar;19(1):78-89 [9917023.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8794-801 [16314639.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):185-91 [16216320.001]
  • [Cites] Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S161-92 [17161157.001]
  • [Cites] Ultrasound Obstet Gynecol. 2007 May;29(5):496-504 [17444557.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2007 Aug;133(2):218-22 [16797823.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4440-7 [17671128.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4194-200 [17698805.001]
  • [Cites] J Clin Epidemiol. 2008 Feb;61(2):125-34 [18177785.001]
  • [Cites] J Clin Epidemiol. 2008 Feb;61(2):135-41 [18177786.001]
  • [Cites] Neural Netw. 2008 Mar-Apr;21(2-3):437-49 [18343309.001]
  • [Cites] Obstet Gynecol. 2009 Feb;113(2 Pt 1):384-94 [19155910.001]
  • [Cites] BMJ. 2009;338:b605 [19477892.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Lancet. 2009 Oct 17;374(9698):1371-82 [19793610.001]
  • [Cites] Epidemiology. 2010 Jan;21(1):128-38 [20010215.001]
  • [Cites] Ultrasound Obstet Gynecol. 2000 Oct;16(5):500-5 [11169340.001]
  • (PMID = 20961457.001).
  • [ISSN] 1471-2288
  • [Journal-full-title] BMC medical research methodology
  • [ISO-abbreviation] BMC Med Res Methodol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2988009
  •  go-up   go-down


62. Hascalik S, Celik O, Sarac K, Meydanli MM, Alkan A, Mizrak B: Metabolic changes in pelvic lesions: findings at proton MR spectroscopic imaging. Gynecol Obstet Invest; 2005;60(3):121-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Spectroscopy analysis of serous, mucinous and undifferentiated carcinoma of the ovary revealed Cho, lactate and lipid signals, but granulosa-theca cell tumor showed only a lipid signal.
  • The Cho signal was obtained from only 3 patients with mature cystic teratoma but none of the other benign ovarian tumors and pelvic abscesses.
  • A lipid signal was detected in 3 patients diagnosed with pelvic abscess and all benign ovarian tumors.
  • CONCLUSION: MRS demonstrates significant differences in metabolite concentration between benign and malignant ovarian tumors and pelvic abscesses.
  • MRS may therefore be helpful in the differential diagnosis of adnexal lesions.
  • [MeSH-major] Magnetic Resonance Spectroscopy. Pelvic Neoplasms / metabolism. Pelvic Neoplasms / pathology
  • [MeSH-minor] Abdominal Abscess / metabolism. Abdominal Abscess / pathology. Adult. Aged. Choline / metabolism. Creatine / metabolism. Dermoid Cyst / metabolism. Dermoid Cyst / pathology. Diagnosis, Differential. Endometriosis / metabolism. Endometriosis / pathology. Female. Granular Cell Tumor / metabolism. Granular Cell Tumor / pathology. Humans. Lipid Metabolism. Middle Aged. Neoplasms, Cystic, Mucinous, and Serous / metabolism. Neoplasms, Cystic, Mucinous, and Serous / pathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Protons. Teratoma / metabolism. Teratoma / pathology

  • Hazardous Substances Data Bank. CREATINE .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 15920339.001).
  • [ISSN] 0378-7346
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Protons; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


63. Ye S, Hao X, Zhou T, Wu M, Wei J, Wang Y, Zhou L, Jiang X, Ji L, Chen Y, You L, Zhang Y, Xu G, Zhou J, Ma D, Wang S: Plexin-B1 silencing inhibits ovarian cancer cell migration and invasion. BMC Cancer; 2010;10:611
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plexin-B1 silencing inhibits ovarian cancer cell migration and invasion.
  • However, whether or not Plexin-B1 expression is involved in human ovarian tumors remains unclear.
  • In the present study, Plexin-B1 expression was explored in benign and malignant human ovarian tumor tissues.
  • In addition, the impact of Plexin-B1 expression on ovarian cancer cell proliferation, migration and invasion were investigated in vitro.
  • METHODS: Plexin-B1 expression was analyzed in normal and benign ovarian tissues and serous ovarian tumors (both borderline and malignant) by immunohistochemical staining, as well as in four human ovarian cancer cell lines (A2780, C13*, SKOV3, and OV2008) by RT-PCR and western blot analyses.
  • RESULTS: Expression levels of Plexin-B1 protein were significantly higher in serous ovarian carcinomas than in normal ovaries or benign ovarian neoplasms, and in the former, Plexin-B1 expression was positively correlated with lymphatic metastasis, and the membrane and cytoplasm of cancer cells stained positively.
  • SKOV3 cells displayed the highest Plexin-B1 expression at both the mRNA and protein levels among the four tested human ovarian cancer cell lines and was selected as a cell model for further in vitro experiments.
  • CONCLUSION: Plexin-B1 expression correlates with malignant phenotypes of serous ovarian tumors, probably via phosphorylation of AKT at Ser473, suggesting that Plexin-B1 might be a useful biomarker and/or a novel therapeutic target.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Gene Silencing. Nerve Tissue Proteins / genetics. Ovarian Neoplasms / genetics. Receptors, Cell Surface / genetics
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Cell Movement. Cell Proliferation. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Proto-Oncogene Proteins c-akt / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12457-62 [11035813.001]
  • [Cites] Mol Cancer. 2009;8:26 [19386116.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3498-504 [11369643.001]
  • [Cites] Trends Immunol. 2001 Dec;22(12):670-6 [11738997.001]
  • [Cites] Sci STKE. 2002 Apr 16;2002(128):re4 [11972358.001]
  • [Cites] Nat Cell Biol. 2002 Sep;4(9):720-4 [12198496.001]
  • [Cites] Ann Hematol. 2002;81 Suppl 2:S74 [12611086.001]
  • [Cites] J Biol Chem. 2004 Jan 16;279(3):1885-91 [14559914.001]
  • [Cites] Dev Cell. 2004 Jul;7(1):107-16 [15239958.001]
  • [Cites] Mol Endocrinol. 2004 Oct;18(10):2570-82 [15243131.001]
  • [Cites] Neuron. 1995 Jun;14(6):1189-99 [7605632.001]
  • [Cites] Nature. 1996 Oct 10;383(6600):525-8 [8849723.001]
  • [Cites] Cell Oncol. 2009;31(6):423-36 [19940359.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11780-5 [8876214.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1238-44 [9515811.001]
  • [Cites] J Cell Biol. 1999 Mar 22;144(6):1235-44 [10087266.001]
  • [Cites] Curr Opin Immunol. 1999 Aug;11(4):387-91 [10448143.001]
  • [Cites] Cell. 1999 Oct 1;99(1):71-80 [10520995.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4321-9 [15632204.001]
  • [Cites] Cell Mol Life Sci. 2005 Jun;62(12):1363-71 [15818466.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Aug-Oct;16(4-5):535-48 [15979925.001]
  • [Cites] Mol Cell Biol. 2005 Aug;25(16):6889-98 [16055703.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1378-83 [10717620.001]
  • [Cites] Mech Dev. 2000 Oct;97(1-2):35-45 [11025205.001]
  • [Cites] Biochem J. 2005 Aug 15;390(Pt 1):125-36 [15839837.001]
  • [Cites] Dev Dyn. 2005 Oct;234(2):393-403 [16145665.001]
  • [Cites] Fertil Steril. 2005 Oct;84 Suppl 2:1210-9 [16210013.001]
  • [Cites] Biochem J. 2006 Mar 1;394(Pt 2):459-64 [16187944.001]
  • [Cites] Endothelium. 2006 Mar-Apr;13(2):81-91 [16728327.001]
  • [Cites] Nat Cell Biol. 2006 Jun;8(6):615-22 [16715077.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9017-22 [16754882.001]
  • [Cites] EMBO Rep. 2006 Jul;7(7):704-9 [16799460.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1115-22 [17317819.001]
  • [Cites] OMICS. 2007 Spring;11(1):41-57 [17411395.001]
  • [Cites] Annu Rev Cell Dev Biol. 2007;23:263-92 [17539753.001]
  • [Cites] J Biol Chem. 2007 Nov 30;282(48):34888-95 [17855350.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 27;104(48):19040-5 [18024597.001]
  • [Cites] J Biol Chem. 2008 Jan 25;283(4):1893-901 [18025083.001]
  • [Cites] Oncology. 2007;72(3-4):172-80 [18097168.001]
  • [Cites] Transl Res. 2008 Mar;151(3):134-40 [18279812.001]
  • [Cites] Protein Sci. 2008 Jun;17(6):1003-14 [18411422.001]
  • [Cites] Am J Pathol. 2008 Aug;173(2):545-60 [18599607.001]
  • [Cites] Mol Biol Cell. 2009 Mar;20(6):1728-36 [19158377.001]
  • [Cites] PLoS One. 2009;4(4):e5052 [19337377.001]
  • [Cites] Curr Biol. 2001 Mar 6;11(5):339-44 [11267870.001]
  • (PMID = 21059203.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / PLXNB1 protein, human; 0 / Receptors, Cell Surface; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ PMC2991310
  •  go-up   go-down


64. Huang CY, Cheng WF, Lee CN, Su YN, Chien SC, Tzeng YL, Hsieh CY, Chen CA: Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor. Anticancer Res; 2006 Nov-Dec;26(6C):4721-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor.
  • The aim of this study was to determine the relationship between mesothelin and clinical pathological characteristics and whether mesothelin can be used as a biomarker for the detection and prognosis of epithelial ovarian carcinoma, or not.
  • PATIENTS AND METHODS: Pre-operative mesothelin and CA125 levels from normal populations, patients with benign ovarian tumors and patients with ovarian carcinomas were measured.
  • RESULTS: Mesothelin levels were higher in cancer patients than in those with benign ovarian tumors or in normal populations.
  • CONCLUSION: Mesothelin might be a new tumor marker for the differential diagnosis of epithelial ovarian carcinoma and a prognostic factorfor the outcome of epithelial ovarian carcinoma patients.
  • [MeSH-major] Membrane Glycoproteins / blood. Ovarian Neoplasms / blood
  • [MeSH-minor] Adult. CA-125 Antigen / blood. Cystadenoma / blood. Cystadenoma / pathology. Epithelial Cells / pathology. Female. GPI-Linked Proteins. Humans. Middle Aged. Neoplasm Staging. Preoperative Care. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214332.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  •  go-up   go-down


65. Bar JK, Słomska I, Rabczyńki J, Noga L, Gryboś M: Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors. Int J Gynecol Cancer; 2009 Nov;19(8):1322-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors.
  • The study investigated the expression of p53 protein phosphorylated at serine 20 (Ser20) and Ser392 and the association between clinicopathological parameters of ovarian neoplasms with respect to p53 protein overexpression.
  • METHODS: p53 protein expression was evaluated on tissues from malignant and benign ovarian tumors.
  • RESULTS: The correlation between p53 protein overexpression and p53-Ser392 phosphorylation was found in ovarian carcinomas (P = 0.001, r = +0.27).
  • In the total group of ovarian carcinomas, significant differences were observed in p53 protein overexpression between well (G1) and poor (G3) tumor grades (P = 0.005) and between serous and endometrioid types of tumor (P = 0.04), whereas p53-Ser20 phosphorylation was associated with advanced International Federation of Gynecology and Obstetrics stage (P = 0.004) and high tumor grade (P = 0.02).
  • In p53-positive ovarian carcinomas, p53-Ser392 phosphorylation was associated with advanced tumor stage (P = 0.02) and high tumor grade (P = 0.049).
  • p53-Ser20 phosphorylation was associated with low tumor grade of p53-positive ovarian carcinomas (P = 0.02) and with high tumor grade of p53-negative ovarian carcinomas (P = 0.02).
  • CONCLUSIONS: These results revealed that p53 phosphorylation at Ser20 and Ser392 is an early event in ovarian tumor development.
  • The authors suggest that the expression of p53 protein phosphorylated at Ser20 and Ser392 in ovarian carcinomas determines their individual clinical features depending on p53 protein status and may be useful biological biomarkers characterizing their behavior.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Serous / metabolism. Endometrial Neoplasms / metabolism. Neoplasms / metabolism. Ovarian Neoplasms / metabolism. Serine / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Phosphorylation. Prognosis. Young Adult


66. Bunyavejchevin S, Phupong V: Laparoscopic surgery for presumed benign ovarian tumor during pregnancy. Cochrane Database Syst Rev; 2006;(4):CD005459
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic surgery for presumed benign ovarian tumor during pregnancy.
  • BACKGROUND: The surgical management of ovarian tumors in pregnancy is similar to that of non-pregnant women.
  • The procedures include resection of the tumor (enucleation), removal of an ovary or ovaries (oophorectomy), or surgical excision of the fallopian tube and ovary (salpingo-oophorectomy).
  • OBJECTIVES: To compare the effects of using laparoscopic surgery for benign ovarian tumor during pregnancy on maternal and fetal health and the use of healthcare resources.
  • SELECTION CRITERIA: Randomized controlled trials with reported data that compared outcomes of laparoscopic surgery for benign ovarian tumor in pregnancy to conventional laparotomy technique.
  • AUTHORS' CONCLUSIONS: The practice of laparoscopic surgery for benign ovarian tumour during pregnancy is associated with benefits and harms.
  • The available case series studies of laparoscopic surgery for benign ovarian tumour during pregnancy provide limited insight into the potential benefits and harms associated with this new surgical technique in pregnancy.
  • Randomized controlled trials are required to provide the most reliable evidence regarding the benefits and harms of laparoscopic surgery for benign ovarian tumour during pregnancy.
  • [MeSH-major] Laparoscopy. Ovarian Neoplasms / surgery. Pregnancy Complications, Neoplastic / surgery

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2013;1:CD005459 [23440802.001]
  • (PMID = 17054259.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 26
  •  go-up   go-down


67. Hossain F, Karim MN, Rahman SM, Khan N, Siddiqui M, Hussain R: Preoperative detection of ovarian cancer by color Doppler ultrasonography and CA 125. Bangladesh Med Res Counc Bull; 2010 Aug;36(2):68-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative detection of ovarian cancer by color Doppler ultrasonography and CA 125.
  • PURPOSE: Early detection of ovarian malignancy is of great clinical importance.
  • The high mortality rate is due to the difficulties with the early detection of ovarian cancer.
  • Current research attempted to assess the accuracy of Color Doppler Sonography and serum CA-125 level as diagnostic tool of ovarian tumor.
  • MATERIALS AND METHODS: In this cross-sectional study, 60 consecutive patients with ovarian tumor attending the Department of Obstetrics and Gynecology of BSMMU were recruited.
  • Following excision, routine histopathology revealed 43.30% malignant (n=26) and 56.7% (n=34) benign ovarian lesion.
  • Sensitivity, specificity, accuracy, positive and negative predictive value of the diagnosis made by CDS, CA125, in the discrimination of the benign and malignant ovarian tumors was calculated.
  • Using Receiver operative characteristics analysis the accuracy of RI, PI, CA 125 and Novel Index in the diagnosis of ovarian tumor (benign or malignant) were assessed.
  • RESULTS: With the Cut-off of < .5, Resistance Index is found to be capable of detecting 92% of malignant cases (sensitivity 91.7), and could detect 89% (specificity 88.9) of benign cases correctly which translates in to 90% accuracy in the diagnosis of ovarian tumor.
  • RI is found to be more sensitive in detection of positive cases (Malignant) and CA125 is found to be more accurate in detection of negative cases (Benign).
  • CONCLUSION: Color Doppler ultra-sonography and CA125 excels in different tasks, the study concludes in favor of concurrent use of the methods for improving efficacy and thus early detection of ovarian malignancy.
  • [MeSH-major] CA-125 Antigen / blood. Ovarian Neoplasms / blood. Ovarian Neoplasms / ultrasonography


68. Song JY, Chen KY, Kim SY, Kim MR, Ryu KS, Cha JH, Kang CS, MacLaughlin DT, Kim JH: The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor protein and mRNA in benign, borderline and malignant ovarian neoplasia. Int J Oncol; 2009 Jun;34(6):1583-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor protein and mRNA in benign, borderline and malignant ovarian neoplasia.
  • This study investigated the expression patterns of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor (MIS/AMHRII) and mRNA in various types of ovarian neoplasia and evaluated the clinical significance of MIS/AMH as a biological response modifier for MIS/AMHR-positive tumors.
  • There was no significant difference in expression intensity between MIS/AMHRII protein and mRNA on all ovarian samples whether benign or malignant.
  • MIS/AMHRII protein and mRNA were weakly expressed on 45.45% of benign ovarian tumors.
  • In borderline tumors, expression rates of MIS/AMHRII protein and mRNA were 77.78% with score 1.22 and 55.56% with score 1, respectively.
  • In malignant ovarian tumors, expression rates of MIS/AMHRII protein and mRNA were 70% with score 1.23 and 75% with score 1.43, respectively.
  • Among malignant ovarian tumors, sex cord stromal tumors showed the highest expression rate and the strongest intensity of MIS/AMHRII protein and mRNA followed by germ cell tumor and epithelial ovarian tumor.
  • Non-epithelial malignant tumors showed stronger expression than that of epithelial tumors (P<0.05, P<0.001, respectively).
  • In serous borderline malignant and malignant tumors, MIS/AMHRII protein and mRNA expression was 63.64 and 81.82% with expression intensity of 1.27 and 1.46, respectively, which were not statistically different from non-epithelial malignant tumors.
  • MIS/AMHRII and MIS/AMHRII mRNA demonstrate significantly variable expression among different ovarian tumor types.
  • Non-epithelial cell tumors show higher expression than those of epithelial cell tumors.
  • The highest expression rate and intensity were observed on sex cord stromal tumors.
  • These data support that MIS/AMH may be used as a biological modifier or therapeutic modulator in MIS/AMHRII-expressed ovarian tumors.
  • [MeSH-major] Anti-Mullerian Hormone / genetics. Gene Expression Regulation, Neoplastic / physiology. Ovarian Neoplasms / genetics. Receptors, Peptide / genetics. Receptors, Transforming Growth Factor beta / genetics
  • [MeSH-minor] Carcinoma / genetics. Carcinoma / metabolism. Carcinoma / pathology. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Ovary / metabolism. Ovary / pathology. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sex Cord-Gonadal Stromal Tumors / genetics. Sex Cord-Gonadal Stromal Tumors / metabolism. Sex Cord-Gonadal Stromal Tumors / pathology. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19424576.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Peptide; 0 / Receptors, Transforming Growth Factor beta; 0 / anti-Mullerian hormone receptor; 80497-65-0 / Anti-Mullerian Hormone
  •  go-up   go-down


69. Leung SW, Yuen PM: Ovarian fibroma: a review on the clinical characteristics, diagnostic difficulties, and management options of 23 cases. Gynecol Obstet Invest; 2006;62(1):1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian fibroma: a review on the clinical characteristics, diagnostic difficulties, and management options of 23 cases.
  • AIM: We review clinical characteristics, diagnostic difficulties, and our experience in the surgical management of ovarian fibromas.
  • METHOD: Twenty-three women with the operative diagnosis of an ovarian fibroma managed between January 1995 and August 2004 were reviewed retrospectively.
  • RESULTS: These patients comprised 1% of all benign ovarian tumors seen over this study period.
  • The diagnosis of an ovarian fibroma or a solid ovarian tumor was correctly made preoperatively in only 5 patients (21.7%).
  • All tumors were unilateral, and the median size was 13 cm.
  • CONCLUSIONS: Gynecologists should be aware of this group of ovarian tumors despite their uncommon occurrence.
  • There are clinical clues to differentiate an ovarian fibroma from uterine fibroid and ovarian malignancy.
  • Surgical removal of these solid ovarian tumors is recommended because of the low probability of malignancy.
  • Minimal-access surgery is an option, especially when the tumor is of moderate or small size.
  • [MeSH-major] Fibroma / diagnosis. Fibroma / pathology. Fibroma / surgery. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / surgery
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Laparoscopy. Laparotomy. Length of Stay. Middle Aged. Postmenopause. Retrospective Studies. Sex Cord-Gonadal Stromal Tumors / diagnosis. Sex Cord-Gonadal Stromal Tumors / pathology. Sex Cord-Gonadal Stromal Tumors / surgery. Time Factors. Treatment Outcome. Tumor Burden

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for ovarian fibroma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 S. Karger AG, Basel
  • (PMID = 16498263.001).
  • [ISSN] 0378-7346
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 13
  •  go-up   go-down


70. Simon I, Katsaros D, Rigault de la Longrais I, Massobrio M, Scorilas A, Kim NW, Sarno MJ, Wolfert RL, Diamandis EP: B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. Gynecol Oncol; 2007 Aug;106(2):334-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression.
  • OBJECTIVE: This study characterizes the expression of the novel biomarker B7-H4 in ovarian cancer tissue, normal ovaries, and benign ovarian tumors, and evaluates its relationship to CA125.
  • METHODS: Ovarian tissue lysates from 251 patients with ovarian carcinoma were assessed for the levels of B7-H4 and CA125 by ELISA assays.
  • For comparison, ovarian tissues from patients with benign ovarian tumors (n=43) and patients with normal ovaries (n=32) were tested.
  • B7-H4 was elevated in tumors of 30 patients with early stage cancer that were negative for CA125.
  • CONCLUSION: B7-H4 expression was low in normal ovaries and in benign tumors while half of early stage and two-thirds of late stage cancers over-expressed B7-H4.
  • The data are consistent with previous observations and support further investigation of B7-H4 in the detection of early stage ovarian cancer either alone, or in combination with CA125.
  • [MeSH-major] Antigens, CD80 / biosynthesis. Biomarkers, Tumor / biosynthesis. CA-125 Antigen / biosynthesis. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Humans. Middle Aged. Neoplasm Staging. V-Set Domain-Containing T-Cell Activation Inhibitor 1

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17498784.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD80; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / V-Set Domain-Containing T-Cell Activation Inhibitor 1; 0 / VTCN1 protein, human
  •  go-up   go-down


71. Green GE, Mortele KJ, Glickman JN, Benson CB: Brenner tumors of the ovary: sonographic and computed tomographic imaging features. J Ultrasound Med; 2006 Oct;25(10):1245-51; quiz 1252-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brenner tumors of the ovary: sonographic and computed tomographic imaging features.
  • OBJECTIVE: The purpose of this study was to describe the sonographic appearance of ovarian Brenner tumors with computed tomographic (CT) correlation.
  • METHODS: Twenty-two female patients (age range, 32-78 years; mean, 58 years) with 25 ovarian Brenner tumors were identified from pathologic records from 1990 to 2005.
  • RESULTS: Tumors ranged in size from 0.3 to 12 cm (mean, 2.5 cm); all were benign.
  • Eight (36%) of 22 patients had a total of 12 associated benign ovarian neoplasms (1 was contralateral); 3 patients had bilateral Brenner tumors.
  • Eight (47%) of 17 tumors were not seen on sonography, and 5 (36%) of 14 were not seen on CT.
  • Of the tumors seen on imaging, most were solid (67% on sonography and 78% on CT).
  • Four tumors appeared at least partially cystic, of which 3 had coexistent cystic ovarian lesions.
  • CONCLUSIONS: Brenner tumors are most often solid neoplasms found incidentally and frequently seen in association with other benign ovarian epithelial neoplasms.
  • [MeSH-major] Brenner Tumor / ultrasonography. Ovarian Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16998096.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC Jr: The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol; 2008 Feb;108(2):402-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
  • OBJECTIVES: The CA125 tumor marker is used to help predict the presence of ovarian cancer in patients with an adnexal mass.
  • Because elevated CA125 levels occur in many benign gynecologic conditions, we set out to identify other novel biomarkers that would increase the sensitivity and specificity of CA125.
  • Of these, 233 patients were eligible for analysis with 67 invasive epithelial ovarian cancers and 166 benign ovarian neoplasms.
  • Mean values for all marker levels except Her2 differed significantly between patients with benign masses and cancer.
  • CONCLUSIONS: As a single tumor marker, HE4 had the highest sensitivity for detecting ovarian cancer, especially Stage I disease.
  • [MeSH-major] Biomarkers, Tumor / blood. Biomarkers, Tumor / urine. Ovarian Neoplasms / blood. Ovarian Neoplasms / urine. Pelvic Neoplasms / blood. Pelvic Neoplasms / urine


73. Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ: Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res; 2005 Nov 15;65(22):10602-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
  • Papillary serous low malignant potential (LMP) tumors are characterized by malignant features and metastatic potential yet display a benign clinical course.
  • The role of LMP tumors in the development of invasive epithelial cancer of the ovary is not clearly defined.
  • The aim of this study is to determine the relationships among LMP tumors and invasive ovarian cancers and identify genes contributing to their phenotypes.
  • Affymetrix U133 Plus 2.0 microarrays (Santa Clara, CA) were used to interrogate 80 microdissected serous LMP tumors and invasive ovarian malignancies along with 10 ovarian surface epithelium (OSE) brushings.
  • Gene expression profiles for each tumor class were used to complete unsupervised hierarchical clustering analyses and identify differentially expressed genes contributing to these associations.
  • The majority of low-grade tumors clustered with LMP tumors.
  • Comparing OSE with high-grade and LMP expression profiles revealed enhanced expression of genes linked to cell proliferation, chromosomal instability, and epigenetic silencing in high-grade cancers, whereas LMP tumors displayed activated p53 signaling.
  • The expression profiles of LMP, low-grade, and high-grade papillary serous ovarian carcinomas suggest that LMP tumors are distinct from high-grade cancers; however, they are remarkably similar to low-grade cancers.
  • Prominent expression of p53 pathway members may play an important role in the LMP tumor phenotype.
  • [MeSH-major] Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / pathology. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology
  • [MeSH-minor] Cluster Analysis. Female. Gene Expression Profiling. Humans. Neoplasm Staging. Oligonucleotide Array Sequence Analysis / methods. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16288054.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA165009; United States / NCI NIH HHS / CA / R33CA103595
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


74. Obayashi Y, Yabushita H, Kanyama K, Noguchi M, Zhuo L, Kimata K, Wakatsuki A: Role of serum-derived hyaluronan-associated protein-hyaluronan complex in ovarian cancer. Oncol Rep; 2008 May;19(5):1245-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of serum-derived hyaluronan-associated protein-hyaluronan complex in ovarian cancer.
  • The objective of this study was to determine if the level of serum hyaluronan (HA), serum-derived HA-associated protein (SHAP)-HA complex, and urinary trypsin inhibitor (UTI) correlate with the clinical outcome of ovarian cancer patients.
  • Serum and urine samples were obtained from 45 patients with ovarian cancer, 22 patients with benign ovarian tumors and 50 healthy women.
  • The levels of HA, SHAP-HA complex, MMP-9 and TIMP-1 were higher in the ovarian cancer group than in the benign ovarian tumor group.
  • In ovarian cancer patients, the levels of HA, SHAP-HA complex and MMP-9 were higher in the stage III/IV group than in the stage I/II group, and the levels of SHAP-HA complex, MMP-9 and TIMP-1 were higher in the non-responder group than in the responder group.
  • The serum concentration of SHAP-HA complex had a significant correlation with HA, MMP-9 and TIMP-1 in ovarian cancer patients.
  • The elevated level of SHAP-HA complex may indicate the prognosis of recurrence and reflect the tumor metastasis associated with MMP-9 in ovarian cancer patients.
  • [MeSH-major] Alpha-Globulins / biosynthesis. Alpha-Globulins / physiology. Gene Expression Regulation, Neoplastic. Hyaluronic Acid / chemistry. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Disease-Free Survival. Female. Glycoproteins / chemistry. Humans. Matrix Metalloproteinase 9 / biosynthesis. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18425383.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Alpha-Globulins; 0 / Glycoproteins; 39346-44-6 / inter-alpha-inhibitor; 80449-32-7 / urinastatin; 9004-61-9 / Hyaluronic Acid; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


75. Zhang S, Lin QD, DI W: Suppression of human ovarian carcinoma metastasis by the metastasis-suppressor gene, BRMS1. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):522-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of human ovarian carcinoma metastasis by the metastasis-suppressor gene, BRMS1.
  • Expression of BRMS1 messenger RNA (mRNA) in multitissue including normal prostate, ovarian, testis, and colon has been detected by northern blot analysis.
  • We hypothesize that the role of BRMS1 in tumor progression may not be limited to breast cancer and melanoma.
  • We previously found that BRMS1 mRNA levels in primary ovarian epithelial carcinomas were significantly lower than that in normal ovarian and benign tumors (P < 0.05), and statistical analysis of BRMS1 mRNA levels revealed that BRMS1 mRNA levels were significantly higher in early tumor stages (I, II) compared with advanced tumor stages (III, IV) in which lymph node or distant metastases were present (P < 0.01).
  • Our data showed that reduced BRMS1 mRNA seems to influence ovarian carcinoma metastatic ability.
  • Therefore, we transfected BRMS1 plasmid into highly malignant ovarian carcinoma cell line, HO-8910PM, and examined cell biologic behaviors including proliferation, adhesion, invasion, and metastasis in vitro and in vivo.
  • BRMS1 expression did not alter the proliferation of HO-8910PM cells in vitro and primary tumor formation in vivo.
  • Also, BRMS1 transfectants form significantly less metastatic to organs of peritoneal cavity in orthotopically implanted ovarian tumor nude models.
  • These data suggested that in addition to its already described role in breast cancer and melanoma, BRMS1 functions as a metastasis-suppressor gene in ovarian carcinoma by modifying several metastatic-associated phenotypes, offering a new target for therapeutic intervention.
  • [MeSH-major] Gene Expression Regulation / physiology. Neoplasm Proteins / physiology. Ovarian Neoplasms / prevention & control
  • [MeSH-minor] Animals. Cell Movement. Cell Proliferation. Disease Models, Animal. Down-Regulation. Female. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Invasiveness. Neoplasms, Glandular and Epithelial / metabolism. Neoplasms, Glandular and Epithelial / prevention & control. Neoplasms, Glandular and Epithelial / secondary. Peritoneal Neoplasms / prevention & control. Peritoneal Neoplasms / secondary. RNA, Messenger / metabolism. Repressor Proteins. Reverse Transcriptase Polymerase Chain Reaction. Transfection. Tumor Cells, Cultured. Tumor Stem Cell Assay

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681721.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BRMS1 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Repressor Proteins
  •  go-up   go-down


76. Sedláková I, Vávrová J, Tosner J, Hanousek L: Lysophosphatidic acid: an ovarian cancer marker. Eur J Gynaecol Oncol; 2008;29(5):511-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lysophosphatidic acid: an ovarian cancer marker.
  • OBJECTIVE: To determine whether lysophosphatidic acid (LPA) can serve as an ovarian cancer marker, we compared plasma LPA levels in ovarian cancer patients, in women with no ovarian pathology, and in women with benign ovarian tumors.
  • METHOD: Capillary electrophoresis with indirect ultraviolet detection was used to analyze the plasma LPA levels of 133 patients (60 patients with ovarian cancer, 43 women without ovarian pathologies and 30 patients with benign ovarian tumors) during a three-year period.
  • RESULTS: Patients with ovarian cancer had a significantly higher plasma LPA level (n=60, median (med) 16.99 micromnol/l, range 4.53-43.21 micromol/l) compared with controls with no ovarian pathology (n=43, med 2.92 micromol/l, range 0.94-22.93 micromnol/l) and patients with benign ovarian tumor (n=30, med 7.73 micromol/l, range 1.12-28.84 micromol/l) (p < 0.001).
  • We found that plasma LPA levels were associated with the International Federation of Gynecology and Obstetrics (FIGO) stage and ovarian cancer histological type.
  • Patients with endometrial ovarian cancer had significantly higher plasma LPA levels in comparison with other histological types of epithelial ovarian carcinoma.
  • CONCLUSION: The plasma LPA level can be a useful marker for ovarian cancer, particularly in the early stages of disease.
  • [MeSH-major] Biomarkers, Tumor / blood. Lysophospholipids / blood. Ovarian Neoplasms / blood

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19051824.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lysophospholipids; 22002-87-5 / lysophosphatidic acid
  •  go-up   go-down


77. Zhang LL, Shao SL, Wu Y: [Expressions of osteopontin and B7-H4 in epithelial ovarian neoplasm and their significance]. Chin J Cancer; 2010 Jan;29(1):25-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expressions of osteopontin and B7-H4 in epithelial ovarian neoplasm and their significance].
  • BACKGROUND AND OBJECTIVE: Epithelial ovarian cancer involves a number of factors.
  • Recent studies have shown that osteopontin (OPN) is related to the occurrence and development of a variety of tumors, but few studies are on ovarian cancer.
  • B7-H4 is a newly identified tumor marker in ovarian cancer.
  • This study explored the expression of OPN and B7-H4 and their clinical significance in epithelial ovarian tumors.
  • METHODS: The expression of OPN and B7-H4 in 15 cases of normal ovarian tissue, 20 of benign ovarian tumor tissue, 20 of borderline ovarian tumor tissue, and 40 of ovarian cancer tissue were detected by immunohistochemistry, and the relationship of OPN and B7-H4 expression to clinical and pathologic features of ovarian cancer was analyzed.
  • RESULTS: The expression of OPN and B7-H4 were significantly higher in ovarian cancer than in borderline and benign tumors (P<0.05).
  • The positive rates of OPN and B7-H4 were significantly higher in poorly differentiated ovarian cancer than in medium and highly differentiated ovarian cancer (P<0.05), and the levels of expression were significantly lower in tissue at stages I and III of ovarian cancer than in stages III and IV (P<0.05).
  • The positive rate of B7-H4 were significantly higher in ovarian serous carcinoma than in the mucinous carcinoma (P<0.05), but did not relate to age and lymph node metastasis.
  • CONCLUSION: The expression of OPN and B7-H4 increased in epithelial ovarian cancer, which could be referenced in the diagnosis of ovarian malignant tumors.
  • [MeSH-major] Cystadenocarcinoma, Serous / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Osteopontin / metabolism. Ovarian Neoplasms / metabolism. V-Set Domain-Containing T-Cell Activation Inhibitor 1 / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adolescent. Adult. Aged. Female. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Ovary / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038306.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / SPP1 protein, human; 0 / V-Set Domain-Containing T-Cell Activation Inhibitor 1; 106441-73-0 / Osteopontin; Ovarian epithelial cancer
  •  go-up   go-down


78. Rask K, Zhu Y, Wang W, Hedin L, Sundfeldt K: Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. Mol Cancer; 2006;5:62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression.
  • There are epidemiological data from subjects using NSAIDs, and experimental evidence supporting the hypothesis of prostaglandins (PGs) as regulators of tumourigenesis in the ovary.
  • One of the end products of PG-synthesis, PGE2, regulates several key-processes, which are characteristic for tumour growth, e.g. angiogenesis, proliferation and apoptosisis.
  • The present study investigated the pathway for PGE2-synthesis and signalling in ovarian tumourigenesis by analysing specimen from normal ovaries (n = 18), benign (B) (n = 8), borderline type (BL) (n = 6) and malignant tumours (AC) (n = 22).
  • RESULTS: The results are in line with earlier studies demonstrating an increase of COX-2 in AC compared to the normal ovary, B and BL tumours.
  • IHC revealed staining of the tumour cells, but also increase of COX-1, COX-2, mPGES-1 and EP1-2 in the stromal compartment of AC (grades: moderately-, poorly- and undifferentiated).
  • This observation suggests interactions between tumour cells and stromal cells (fibroblasts, immune cells), e.g. paracrine signalling mediated by growth factors, cytokines and possibly PGs.
  • CONCLUSION: The increases of COX-1, COX-2, mPGES-1 and EP1-2 in epithelial ovarian cancer, supports the hypothesis that PGE2-synthesis and signalling are of importance for malignant transformation and progression.
  • [MeSH-major] Dinoprostone / biosynthesis. Ovarian Neoplasms / metabolism. Signal Transduction / physiology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cyclooxygenase 1 / metabolism. Cyclooxygenase 2 / metabolism. Densitometry. Disease Progression. Epithelial Cells / pathology. Female. Humans. Immunoblotting. Immunohistochemistry. Intramolecular Oxidoreductases / metabolism. Neoplasm Staging. Ovary / metabolism. Receptors, Prostaglandin E / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Soc Gynecol Investig. 2002 May-Jun;9(3):168-73 [12009392.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 2002;21(2):149-53 [12086401.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1205-11 [12181243.001]
  • [Cites] J Reprod Immunol. 2002 Oct-Nov;57(1-2):47-60 [12385833.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):906-11 [12615701.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1423-9 [14508829.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1298-304 [14520463.001]
  • [Cites] Prog Lipid Res. 2004 Jan;43(1):3-35 [14636669.001]
  • [Cites] Oncogene. 2003 Nov 27;22(54):8653-61 [14647459.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2607-23 [14669280.001]
  • [Cites] Oncol Rep. 2004 Feb;11(2):309-13 [14719060.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):538-45 [14760075.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):622-7 [14766256.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4670-9 [15269139.001]
  • [Cites] Acta Obstet Gynecol Scand. 2004 Sep;83(9):783-95 [15315588.001]
  • [Cites] Reproduction. 2004 Nov;128(5):607-14 [15509706.001]
  • [Cites] Lancet. 1971 Jul 17;2(7716):163 [4104488.001]
  • [Cites] Gynecol Oncol. 1983 Dec;16(3):340-5 [6360817.001]
  • [Cites] Gynecol Obstet Invest. 1984;18(5):225-9 [6396175.001]
  • [Cites] Prostaglandins. 1985 May;29(5):665-72 [3859890.001]
  • [Cites] Int J Cancer. 1997 Jun 20;74(3):275-80 [9221804.001]
  • [Cites] J Histochem Cytochem. 1998 Jan;46(1):77-84 [9405496.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1240-8 [10098766.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10501-6 [10468638.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 1;91(17):1459-67 [10469746.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] Br J Cancer. 2005 May 23;92(10):1927-33 [15870720.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2005 Aug;73(2):103-11 [15963707.001]
  • [Cites] Oncogene. 2005 Dec 1;24(54):7991-8002 [16044148.001]
  • [Cites] Nucleic Acids Res. 2006;34(1):217-31 [16397300.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1884-91 [16287068.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):130-40 [16491072.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2527-31 [16510568.001]
  • [Cites] Curr Pharm Des. 2006;12(8):943-54 [16533161.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Am J Obstet Gynecol. 2005 Mar;192(3):819-25 [15746677.001]
  • [Cites] Oncol Rep. 2005 Apr;13(4):559-83 [15756426.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2234-42 [15781636.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3735-44 [15867369.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3250-6 [15867220.001]
  • [Cites] J Reprod Fertil. 2000 Mar;118(2):375-85 [10864803.001]
  • [Cites] Epidemiology. 2000 Mar;11(2):111-7 [11021606.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):849-53 [11238034.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:661-90 [11264472.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2328-34 [11280806.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):255-88 [11294827.001]
  • [Cites] Int J Mol Med. 2001 Jul;8(1):31-6 [11408945.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2496-504 [11489832.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1048-51 [11533709.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7305-9 [11585770.001]
  • [Cites] Int J Mol Med. 2001 Dec;8(6):603-6 [11712072.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):202-9 [11801560.001]
  • [Cites] Annu Rev Physiol. 2002;64:69-92 [11826264.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):893-903 [11891188.001]
  • (PMID = 17107625.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Prostaglandin E; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.99.3 / prostaglandin-E synthase; K7Q1JQR04M / Dinoprostone
  • [Other-IDs] NLM/ PMC1657027
  •  go-up   go-down


79. Tomov S, Popovska S, Veselinova T, Gorchev G, Velkova A: [Immunohistochemical analysis of epidermal growth factor receptors expression in malignant ovarian tumors]. Akush Ginekol (Sofiia); 2005;44 Suppl 2:42-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunohistochemical analysis of epidermal growth factor receptors expression in malignant ovarian tumors].
  • OBJECTIVE: To study the frequency of EGFR expression in patients having malignant and benign ovarian tumors and to analyze its relation to some clinico-pathological factors.
  • MATERIAL AND METHODS: In a prospective study 71 patients with malignant and 19 with benign ovarian tumors were included for the period 1999-2004.
  • RESULTS: The frequency of EGFR expression for the malignant ovarian tumours was 62.9% compared to 36.8% for the benign ones (p = 0.042).
  • The patients with peritoneal washing positive for tumour cells and those with progressing cancer express EGFR significantly more frequently, 77% and 75%, respectively (p = 0.05).
  • CONCLUSION: Malignant ovarian tumours have significantly greater frequency of EGFR expression compared to benign ovarian tumours.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Ovarian Neoplasms / metabolism. Receptor, Epidermal Growth Factor / biosynthesis
  • [MeSH-minor] Disease-Free Survival. Female. Humans. Immunohistochemistry. Neoplasm Metastasis. Prospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16028404.001).
  • [ISSN] 0324-0959
  • [Journal-full-title] Akusherstvo i ginekologii︠a︡
  • [ISO-abbreviation] Akush Ginekol (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


80. Jazaeri AA, Ferriss JS, Bryant JL, Dalton MS, Dutta A: Evaluation of EVI1 and EVI1s (Delta324) as potential therapeutic targets in ovarian cancer. Gynecol Oncol; 2010 Aug 1;118(2):189-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of EVI1 and EVI1s (Delta324) as potential therapeutic targets in ovarian cancer.
  • Overexpression of EVI1 in ovarian cancer has led to a proposed oncogenic role.
  • Our objective was to evaluate the therapeutic potential of EVI1 and EVI1s (also known as Delta324) in ovarian cancer.
  • METHODS: Expression of EVI1 mRNA and protein isoforms was evaluated in ovarian cancers, normal ovaries, benign ovarian neoplasms, and fallopian tube fimbria.
  • RESULTS: EVI1 and EVI1s mRNAs were ubiquitously expressed in ovarian cancers and benign gynecologic tissues examined, with highest expression of both isoforms noted in the cancer samples.
  • In contrast, EVI1 protein isoform levels were undetectable in normal ovarian tissues, and highest in serous ovarian cancers.
  • EVI1 protein expression patterns were similar between serous ovarian cancer samples, fallopian tube fimbria, and benign neoplasms.
  • Total and isoform selective knockdown of EVI1 isoforms in EVI1 expressing ovarian cancer cells had no effect on proliferation, cisplatin-induced apoptosis, or gamma-H2AX levels in ovarian cancer cells.
  • CONCLUSION: Our data do not support a role for EVI1 or EVI1s in ovarian cancer cell proliferation or response to DNA damage.
  • Further research is required before EVI1 can be considered an oncogene or a therapeutic target in ovarian cancer.
  • [MeSH-major] DNA-Binding Proteins / biosynthesis. Ovarian Neoplasms / metabolism. Transcription Factors / biosynthesis
  • [MeSH-minor] Apoptosis / drug effects. Apoptosis / genetics. Cell Growth Processes / drug effects. Cell Growth Processes / genetics. Cell Line, Tumor. Cisplatin / pharmacology. DNA Damage. Drug Delivery Systems. Female. Gene Knockdown Techniques. Humans. Middle Aged. Protein Isoforms. Proto-Oncogenes / genetics. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20462630.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MECOM protein, human; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Transcription Factors; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


81. Staats PN, Coutts MA, Young RH: Primary ovarian mucinous cystic tumor with prominent theca cell proliferation and focal granulosa cell tumor in its stroma: case report, literature review, and comparison with Sertoli-Leydig cell tumor with heterologous elements. Int J Gynecol Pathol; 2010 May;29(3):228-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary ovarian mucinous cystic tumor with prominent theca cell proliferation and focal granulosa cell tumor in its stroma: case report, literature review, and comparison with Sertoli-Leydig cell tumor with heterologous elements.
  • A 73-year-old woman was found to have a 22 cm unilateral multilocular mucinous cystic tumor of the ovary.
  • Microscopic examination showed a routine appearance of the epithelial component, which ranged from benign to borderline to low-grade carcinoma.
  • The stromal component was unusual because of a striking cellular theca cell component in the stroma, which, in turn, merged with a component of adult granulosa cell tumor.
  • The "parent" neoplasm in this case and 3 other similar cases in the literature appears to be the mucinous neoplasm, in contrast with the other example of mucinous neoplasia associated with sex cord neoplasia, the Sertoli-Leydig cell tumor with heterologous elements, in which the "parent" neoplasm is likely the Sertoli-Leydig cell tumor.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Granulosa Cell Tumor / pathology. Ovarian Neoplasms / pathology. Sertoli-Leydig Cell Tumor / pathology. Thecoma / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20407320.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Liguang Z, Peishu L, Hongluan M, Hong J, Rong W, Wachtel MS, Frezza EE: Survivin expression in ovarian cancer. Exp Oncol; 2007 Jun;29(2):121-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survivin expression in ovarian cancer.
  • AIM: To examine the expression of survivin in benign ovarian tumors, ovarian carcinomas of different stages.
  • METHODS: We screened the expression of survivin mRNA by reverse transcription polymerase chain reaction in 114 ovarian tissue samples.
  • RESULTS: No survivin mRNA was expressed in all normal ovarian specimens, while it appeared in 73% of ovarian carcinomas, 47% of borderline ovarian carcinomas and 19% of benign ovarian tumors.
  • In tissues with positive expression of survivin, we also found that mean survivin mRNA expression levels were higher in ovarian carcinomas than that in benign ovarian tumors and borderline ovarian carcinoma tissues (P < 0.001).
  • Among ovarian carcinomas, the high survivin mRNA expression levels correlated with the clinical stages, differentiation grade, lymph node metastasis, but not - with ascites and histological type.
  • CONCLUSION: Our study suggest that survivin is associated with progression of ovarian carcinoma.
  • [MeSH-major] Cystadenoma, Mucinous / metabolism. Cystadenoma, Serous / metabolism. Neoplasm Proteins / biosynthesis. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Carcinoma / metabolism. Carcinoma / pathology. Disease Progression. Female. Humans. Middle Aged. Neoplasm Staging. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17704744.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


83. Zhang J, Li YL, Zhou CY, Hu YT, Chen HZ: Expression of octamer-4 in serous and mucinous ovarian carcinoma. J Clin Pathol; 2010 Oct;63(10):879-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of octamer-4 in serous and mucinous ovarian carcinoma.
  • AIMS: To assess the expression of Oct4 in epithelial ovarian tumours.
  • METHODS: Expression of Oct4 was evaluated by immunohistochemistry in 460 cases of various epithelial ovarian lesions as well as 35 cases of normal fallopian tube epithelium.
  • RESULTS: Oct4 expression was significantly increased from normal epithelium (both ovarian epithelium and fallopian tube epithelium) to benign and borderline cystadenoma to carcinoma in the serous lesion subgroup.
  • CONCLUSION: Results suggest that Oct4 expression may contribute to the initiation, promotion and progression of serous ovarian carcinoma; it might be a useful biomarker for the diagnosis and outcome prediction of serous ovarian carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Cystadenoma / metabolism. Octamer Transcription Factor-3 / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Disease Progression. Epithelium / metabolism. Fallopian Tubes / metabolism. Female. Humans. Neoplasm Proteins / metabolism. Neoplasm Staging. Ovary / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20876318.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human
  •  go-up   go-down


84. Lee S, Garner EI, Welch WR, Berkowitz RS, Mok SC: Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma. Gynecol Oncol; 2007 Aug;106(2):311-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma.
  • OBJECTIVE: Unlike other histological types of epithelial ovarian carcinoma, ovarian clear cell carcinoma is known to have very poor response to therapy even when discovered in its early stages.
  • Since tumor hypoxia has been shown to be strongly associated with poor prognosis, deregulation of the representative factor of tissue hypoxia; hypoxia-inducible factor 1 alpha (HIF-1alpha) and related protein; Von Hippel-Lindau (VHL) may be associated with poor prognosis of ovarian clear cell carcinoma.
  • METHODS: Immunolocalization of both HIF-1alpha and VHL was performed on 56 cases of paraffin-embedded tissue sections of four different histological types of epithelial ovarian carcinoma and 5 cases of benign ovarian tumors as a control.
  • Quantitative RT-PCR analysis of both HIF1A and VHL was performed on RNA isolated from 61 microdissected frozen tissues of four different histological types of epithelial ovarian carcinoma and 6 cases of normal ovarian epithelial cells.
  • RESULTS: HIF-1alpha expression levels were significantly higher in ovarian clear cell carcinoma than in other histological types (P=0.001).
  • There was a negative correlation between HIF-1alpha and VHL in serous (r=-0.661, P=0.027) and in endometrioid carcinoma (r=-0.657 P=0.039), but no correlation was found between HIF-1alpha and VHL expression levels in ovarian clear cell carcinoma (P=0.60).
  • CONCLUSIONS: The results suggest that the role of hypoxia may change according to the histological type of ovarian carcinoma.
  • High expression of HIF-1alpha and its independence from VHL in ovarian clear cell carcinoma may confer chemoresistance in this histological type.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5830-5 [10582706.001]
  • [Cites] Med Hypotheses. 2006;66(2):380-3 [16229963.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):411-21 [10934146.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1830-2 [11280732.001]
  • [Cites] Science. 2001 Apr 20;292(5516):468-72 [11292861.001]
  • [Cites] Biochem J. 2002 Feb 15;362(Pt 1):71-9 [11829741.001]
  • [Cites] Cancer. 2003 Mar 15;97(6):1573-81 [12627523.001]
  • [Cites] Int J Cancer. 2003 Jun 10;105(2):176-81 [12673675.001]
  • [Cites] Cancer Treat Rev. 2003 Aug;29(4):297-307 [12927570.001]
  • [Cites] Cancer. 1977 Dec;40(6):3019-29 [589565.001]
  • [Cites] CA Cancer J Clin. 1980 Jan-Feb;30(1):2-15 [6766347.001]
  • [Cites] Gynecol Oncol. 1989 Nov;35(2):199-203 [2807010.001]
  • [Cites] Gynecol Oncol. 1993 Nov;51(2):141-9 [8276286.001]
  • [Cites] Nat Genet. 1994 May;7(1):85-90 [7915601.001]
  • [Cites] Hum Mol Genet. 1994 Dec;3(12):2169-73 [7881415.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4 [7539918.001]
  • [Cites] Gynecol Oncol. 1996 Mar;60(3):412-7 [8774649.001]
  • [Cites] Cancer. 1996 Nov 15;78(10):2157-63 [8918409.001]
  • [Cites] Kidney Int. 1997 Feb;51(2):560-3 [9027739.001]
  • [Cites] Nature. 1998 Jul 30;394(6692):485-90 [9697772.001]
  • [Cites] Gynecol Oncol. 1998 Aug;70(2):255-8 [9740700.001]
  • [Cites] EMBO J. 1998 Nov 16;17(22):6573-86 [9822602.001]
  • [Cites] Nature. 1999 May 20;399(6733):271-5 [10353251.001]
  • [Cites] Clin Chem. 2005 Oct;51(10):1973-81 [16123149.001]
  • [Cites] Sci STKE. 2005 Oct 18;2005(306):re12 [16234508.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):343-7 [16051334.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2606-18 [10861440.001]
  • (PMID = 17532031.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R33 CA103595; United States / NCI NIH HHS / CA / R33 CA103595-04; United States / NCI NIH HHS / CA / CA103595-04; United States / NCI NIH HHS / CA / CA105009-030002; United States / NCI NIH HHS / CA / P50 CA105009; United States / NCI NIH HHS / CA / P50 CA105009-030002; United States / PHS HHS / / P50105009; United States / NCI NIH HHS / CA / R01 CA133057; United States / NCI NIH HHS / CA / R33CA103595
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / RNA, Messenger; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  • [Other-IDs] NLM/ NIHMS28316; NLM/ PMC1995602
  •  go-up   go-down


85. Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ: Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev; 2005 Feb;14(2):306-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
  • Epithelial ovarian cancer (EOC) is the leading cause of death among all gynecologic cancers in the United States.
  • Serum cancer antigen 125 (CA125) and a soluble isoform of the epidermal growth factor receptor (p110 sEGFR) have been studied individually as biomarkers of ovarian cancer.
  • In this study, we compare serum CA125 levels and sEGFR concentrations in women with EOC to women with benign gynecologic conditions of ovarian and non-ovarian origin.
  • We show that serum sEGFR concentrations are lower in patients with EOC than in women with benign gynecologic conditions, whereas serum CA125 levels are higher in patients to EOC compared with women with benign gynecologic conditions.
  • These data also reveal that age and serum sEGFR concentrations modify the association between CA125 levels and EOC versus benign gynecologic disease.
  • Hence, age- and sEGFR-dependent CA125 cutoff thresholds improve the ability of CA125 to discern EOC patients from women with benign ovarian tumors and non-ovarian gynecologic conditions.
  • Our analyses show that parallel testing with fixed sEGFR and CA125 cutoff thresholds optimizes sensitivity to detect EOC, whereas serial testing with age- and sEGFR-dependent CA125 cutoff thresholds optimizes test specificity, and overall accuracy to discern patients with EOC from women with benign ovarian and non-ovarian gynecologic conditions.
  • The combined use of serologic sEGFR and CA125, thus, has improved utility for screening and diagnosing EOC, which may increase the positive predictive value of a multimodal screening program that incorporates these biomarkers to detect and subsequently differentiate benign from malignant ovarian tumors.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Ovarian Neoplasms / diagnosis. Receptor, Epidermal Growth Factor / blood

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1583
  • (PMID = 15734951.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517; United States / NCI NIH HHS / CA / KO7 CA82520; United States / PHS HHS / / R01 57534; United States / NCI NIH HHS / CA / R03 CA82091; United States / NCI NIH HHS / CA / R21 CA82520; United States / NCI NIH HHS / CA / UO1 CA85133
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Protein Isoforms; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


86. Steffensen KD, Waldstrøm M, Olsen DA, Corydon T, Lorentzen KA, Knudsen HJ, Jeppesen U, Brandslund I, Jakobsen A: Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors. Clin Cancer Res; 2008 Jun 1;14(11):3278-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors.
  • PURPOSE: Dysfunction of the epidermal growth factor (EGF) complex is essential to the growth and development of many human tumors.
  • Overexpression of the EGF receptor (EGFR) is a characteristic finding in a considerable number of solid tumors and often signalizes poor prognosis.
  • There is a major disagreement among researchers about both the frequency and possible clinical importance of EGFR overexpression in ovarian cancer.
  • EGFRvIII has not been found in normal tissue, and consequently, it is an attractive tumor-specific candidate for molecular targeted treatment.
  • The literature dealing with this mutation in ovarian cancer has been very sparse.
  • The samples included 99 ovarian/peritoneal/tuba cancers, 17 ovarian borderline tumors, 66 benign ovarian tumors, 15 other cancer types, 24 normal ovarian biopsies, and 4 miscellaneous.
  • CONCLUSIONS: The EGFRvIII mutation seems to be very rare in ovarian tissue.
  • Our data indicate that EGFRvIII is not a part of the malignant phenotype in ovarian cancer and should not be pursued as a therapeutic target for treatment of this disease.
  • [MeSH-major] Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adult. Aged. Blotting, Western. Electrophoresis, Polyacrylamide Gel. Female. Gene Expression. Humans. Middle Aged. Mutation. Neoplasm Staging. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18519753.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / epidermal growth factor receptor VIII; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


87. Guo RX, Qiao YH, Zhou Y, Li LX, Shi HR, Chen KS: Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer. Pathol Int; 2008 Dec;58(12):749-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer.
  • AKT plays an important role in malignant behavior of tumors.
  • The purpose of the present study was to determine the expression of phosphorylated AKT (P-AKT) and nuclear factor-kappaB (NF-kappaB) p65 and their association with clinicopathological parameters and prognosis in epithelial ovarian tumor.
  • On immunohistochemistry 115 samples of ovarian tissue that included 68 specimens of epithelial ovarian cancer, 12 of borderline tumor, 24 of epithelial benign tumor and 11 of normal ovary, were evaluated.
  • Sixty-three patients with ovarian cancer were followed up from 7 to 68 months.
  • The positive expression rate of P-AKT and NF-kappaB p65 were higher in epithelial ovarian cancer than in normal ovarian tissue (P<0.01).
  • Elevated expression of P-AKT was negatively correlated with the survival of ovarian cancer patients, but it was not an independent prognostic factor after multivariate analysis.
  • Overexpression of P-AKT and NF-kappaB p65 were involved in the carcinogenesis and metastasis of ovarian cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Ovarian Neoplasms / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Transcription Factor RelA / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Ovary / metabolism. Ovary / pathology. Phosphorylation. Prognosis. Survival Rate. Up-Regulation. Young Adult


88. Luo J, Peng ZL, Yang KX, Wang H, Yang H, Dong DD, Yao XY: [Relation between the expression of hypoxia inducible factor-1alpha and angiogenesis in ovarian cancer using tissue microarray]. Zhonghua Fu Chan Ke Za Zhi; 2005 Jan;40(1):38-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relation between the expression of hypoxia inducible factor-1alpha and angiogenesis in ovarian cancer using tissue microarray].
  • OBJECTIVE: To study the relation between the expression of hypoxia inducible factor-1alpha (HIF-1alpha)and angiogenesis in ovarian cancer.
  • METHODS: The expressions of HIF-1alpha mRNA, vascular endothelial growth factor (VEGF), and CD(34) in 295 patients with epithelial ovarian tumors were analyzed by tissue microarray technology, in situ hybridization and immunohistochemistry, and compared with those of 13 normal ovarian tissue samples.
  • RESULTS: The expressions of HIF-1alpha mRNA were observed in 0, 13.2%, 42.1% and 81.9% of normal ovarian tissue, benign, borderline and malignant ovarian tumors respectively.
  • Expression rates of HIF-1alpha mRNA in borderline and invasive tumors were significantly higher than those in normal ovarian tissues and benign tumors (P < 0.01).
  • Close positive relation was observed between the expression of HIF-1alpha mRNA and tumor histological grade (r = 0.246, P < 0.01).
  • CONCLUSION: HIF-1alpha may play a role in angiogenesis of ovarian carcinoma, and may promote the development of the carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / biosynthesis. Neovascularization, Pathologic. Ovarian Neoplasms / metabolism. Ovary / metabolism
  • [MeSH-minor] Adult. Aged. Epithelium / metabolism. Epithelium / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. RNA, Messenger / biosynthesis. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15774091.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


89. Nam EJ, Yun MJ, Oh YT, Kim JW, Kim JH, Kim S, Jung YW, Kim SW, Kim YT: Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI. Gynecol Oncol; 2010 Mar;116(3):389-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI.
  • PURPOSE: To compare the diagnostic accuracy of positron emission tomography/computed tomography (PET/CT), pelvic Doppler ultrasonography (US), abdomino-pelvic computed tomography (CT), and pelvic magnetic resonance imaging (MRI) for detection of ovarian cancer and to assess the role of PET/CT in evaluating the dissemination of ovarian cancer.
  • PATIENTS AND METHODS: One hundred thirty-three women suspected to have ovarian cancer were enrolled in a prospective study before surgery between March 2005 and August 2007.
  • RESULTS: Histopathology showed benign tumors in 25 patients, borderline tumors in 13 patients, and malignant tumors in 95 patients.
  • In distinguishing malignant/borderline from benign ovarian tumors, the accuracy of PET/CT (0.921) was higher than that of pelvis US (0.830) and abdomino-pelvic CT or pelvis MRI (0.749; P=0.013).
  • Radiologic staging by PET/CT was concordant with surgical staging in 78% of patient and PET/CT revealed 15 (15.8%) unpredicted extra-abdominal lymph node metastasis in 95 patients with ovarian cancer.
  • In addition, PET/CT detected new, unexpected co-existing malignant tumors in five (3.8%) cases including two thyroid tumors, two breast tumors, and one pancreatic neuroendocrine cancer.
  • CONCLUSION: PET/CT is superior to pelvis US, abdomino-pelvic CT, and pelvic MRI for diagnosis of malignant ovarian tumors and is useful in revealing metastatic ovarian cancer and co-existing malignant tumors.
  • Therefore, we suggest that PET/CT could be used during pre-operative evaluation of patients suspected to have ovarian cancer.
  • [MeSH-major] Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Fluorodeoxyglucose F18. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. ROC Curve. Radiopharmaceuticals. Tomography, X-Ray Computed. Ultrasonography, Doppler. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19926121.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


90. Byrne JA, Balleine RL, Schoenberg Fejzo M, Mercieca J, Chiew YE, Livnat Y, St Heaps L, Peters GB, Byth K, Karlan BY, Slamon DJ, Harnett P, Defazio A: Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. Int J Cancer; 2005 Dec 20;117(6):1049-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer.
  • Recurrent chromosome 8q gain in ovarian carcinoma is likely to reflect the existence of multiple target loci, as the separate gain of chromosome bands 8q21 and 8q24 has been reported in independent studies.
  • Since tumor protein D52 (TPD52) has been identified as a chromosome 8q21 amplification target in breast and prostate carcinoma, we compared TPD52 expression in normal ovarian epithelium (n = 9), benign serous adenomas (n = 11), serous borderline tumors (n = 6) and invasive carcinomas of the major histologic subtypes (n = 57) using immunohistochemistry.
  • These analyses revealed that all normal ovarian epithelium samples and benign serous tumors were predominantly TPD52-negative, whereas TPD52 was overexpressed in most (44/57; 77%) ovarian carcinomas regardless of histologic subtype.
  • TPD52 therefore represents a novel molecular marker in ovarian cancer, which is broadly expressed across the different histologic subtypes and whose upregulation frequently reflects increased TPD52 copy number.
  • [MeSH-major] Gene Amplification / genetics. Gene Expression. Neoplasm Proteins / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Biomarkers, Tumor / analysis. CA-125 Antigen / blood. Chromosomes, Human, Pair 8. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Middle Aged. Ovary / chemistry

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 15986428.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Neoplasm Proteins; 0 / TPD52 protein, human
  •  go-up   go-down


91. Agaba EI, Ekwempu CC, Ugoya SO, Echejoh GO: Meigs' syndrome presenting as haemorrhagic pleural effusion. West Afr J Med; 2007 Jul-Sep;26(3):253-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The association of a benign ovarian tumor with ascites and hydrothorax that resolve after tumor resection, known as Meigs syndrome is a rare clinical entity.
  • Rarer still is the haemorrhagic form of the syndrome OBJECTIVE: To describe a case of benign ovarian tumour associated with ascites and bloody pleural effusion.
  • RESULTS: The physical examination and a pelvic ultrasonographic scan revealed ascites in addition to a right sided ovarian mass.
  • The pleural effusion and ascites resolved spontaneously thus confirming the diagnosis of Meigs' syndrome.
  • CONCLUSION: Meigs' syndrome should be considered in the differential diagnosis in female patients with hemorrhagic pleural effusion.
  • [MeSH-major] Hemothorax / diagnosis. Meigs Syndrome / diagnosis. Pleural Effusion / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Fibroma / diagnosis. Fibroma / surgery. Hemorrhage / diagnosis. Hemorrhage / etiology. Hemorrhage / surgery. Humans. Ovarian Neoplasms / ultrasonography. Ovariectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18399347.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


92. Garg K, Soslow RA, Rivera M, Tuttle MR, Ghossein RA: Histologically bland "extremely well differentiated" thyroid carcinomas arising in struma ovarii can recur and metastasize. Int J Gynecol Pathol; 2009 May;28(3):222-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eight patients presented with pelvic-related symptoms whereas 2 were incidentally discovered during pregnancy, all with disease confined to the ovary.
  • Two of the 10 thyroid carcinomas relapsed after an initial diagnosis of "benign" struma.
  • Both occurred in young women with ovarian cysts discovered during pregnancy.
  • Both patients presented with disseminated PTC 3 and 4 years after the initial diagnosis, involving the pelvis in both cases and also the liver parenchyma in 1 case.
  • The 2 patients received radioactive iodine therapy after thyroidectomy and are both alive with disease 6 years after diagnosis.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Pregnancy Complications, Neoplastic / pathology. Struma Ovarii / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620939.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Isotopes
  •  go-up   go-down


93. Zou JF, Li JY, Wu XW, Chen SY: [Effects of different anesthesia and analgesia on erythrocyte immune function of patients with ovarian benign tumor treated by laparoscopic therapeutic]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 Dec;26(12):1252-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of different anesthesia and analgesia on erythrocyte immune function of patients with ovarian benign tumor treated by laparoscopic therapeutic].
  • AIM: To investigate the effects of different anesthesia and analgesia on erythrocyte immune function of patients with ovarian benign tumor treated by laparoscopic therapeutic.
  • METHODS: 120 patients with ovarian benign tumor treated by laparoscopic therapeutic were randomly divided into two groups with 60 cases each.In group A, patients received general anesthesia eombined with thoracic epidural anesthesia during surgery, patients in group B received general anesthesia.
  • CONCLUSION: Anesthesia may harm on erythroeyte immune function of patients with ovarian benign tumor treated by laparoscopic therapeutic.
  • [MeSH-major] Analgesia / adverse effects. Anesthesia / adverse effects. Erythrocytes / immunology. Laparoscopy. Ovarian Neoplasms / immunology. Ovarian Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Anesthesia.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21138693.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  •  go-up   go-down


94. Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, Lee K: Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother; 2009 Jan;58(1):15-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment.
  • PURPOSE: Inflammatory cells can both suppress and stimulate tumor growth, and the influence of inflammatory cells on clinical outcome has been the focus of many studies.
  • The purpose of this study was to evaluate the effectiveness of the neutrophil to lymphocyte ratio (NLR), a measure of the systemic inflammatory response, as an additional discriminative biomarker in epithelial ovarian cancer and to determine whether it predicts survival and recurrence.
  • METHODS: We studied 192 patients with epithelial ovarian cancer, 173 with benign ovarian tumors, 229 with benign gynecologic disease, and 405 healthy controls.
  • In epithelial ovarian cancer, the diagnostic usefulness of NLR, in combination with CA125, was evaluated.
  • RESULTS: Preoperative NLR in ovarian cancer subjects (mean 6.02) was significantly higher than that in benign ovarian tumor subjects (mean 2.57), benign gynecologic disease subjects (mean 2.55), and healthy controls (mean 1.98) (P < 0.001).
  • The sensitivity and specificity of NLR in detecting ovarian cancer was 66.1% (95% CI, 59.52-72.68%) and 82.7% (95% CI, 79.02-86.38%), respectively (cutoff value: 2.60).
  • In early stage ovarian cancer, CA125 was not elevated in 19 out of 49 patients.
  • CONCLUSIONS: Our findings provide evidence for the association between NLR and epithelial ovarian cancer.
  • Preoperative NLR, in combination with CA125, may represent a simple and cost-effective method of identifying ovarian cancers, and an elevated NLR may predict an adverse outcome in ovarian cancer.
  • [MeSH-major] Biomarkers, Tumor. Lymphocyte Count. Neoplasms, Glandular and Epithelial / pathology. Neutrophils / cytology. Ovarian Neoplasms / pathology


95. Dede M, Gungor S, Yenen MC, Alanbay I, Duru NK, Haşimi A: CA19-9 may have clinical significance in mature cystic teratomas of the ovary. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):189-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CA19-9 may have clinical significance in mature cystic teratomas of the ovary.
  • The objective of this study was to evaluate size, bilaterality, histopathologic origin, and the serum levels of some tumor markers in patients with mature cystic teratomas (MCTs) of the ovary.
  • The mean tumor diameter was 7.2 +/- 4.5 cm (median 5; range 3-20).
  • Ovarian MCTs were diagnosed especially during the reproductive period.
  • CA19-9 may be the only important marker in the diagnosis of MCTs.
  • Since levels of CA19-9 and CA125 may be elevated in both benign and malignant conditions, interpretation of these findings must be made in light of the clinical condition of the patient.
  • [MeSH-major] Biomarkers, Tumor / analysis. CA-19-9 Antigen / genetics. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology. Teratoma / genetics. Teratoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy, Needle. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Ovariectomy / methods. Predictive Value of Tests. Preoperative Care. Probability. Prognosis. Retrospective Studies. Risk Assessment. Sensitivity and Specificity. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445632.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen
  •  go-up   go-down


96. Akçay T, Dinçer Y, Alademir Z, Aydinli K, Arvas M, Demirkiran F, Kösebay D: Significance of the O6-methylguanine-DNA methyltransferase and glutathione S-transferase activity in the sera of patients with malignant and benign ovarian tumors. Eur J Obstet Gynecol Reprod Biol; 2005 Mar 1;119(1):108-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of the O6-methylguanine-DNA methyltransferase and glutathione S-transferase activity in the sera of patients with malignant and benign ovarian tumors.
  • OBJECTIVE: To demonstrate O6-methylguanine-DNA methyltransferase (MGMT) and glutathione S-transferase (GST) activities by analyzing the sera separately obtained from patients with malignant ovarian tumors, benign ovarian tumors, and healthy individuals.
  • STUDY DESIGN: Fourty-nine patients with ovarian cancer, nine patients with benign tumors, and 22 healthy women were included in this study.
  • Blood samples were obtained from all the subjects in the malignant-tumor, benign-tumor, and control groups.
  • Patients with malignant tumors underwent second and third phlebotomies one week following the surgery and after the chemotherapy regimen, respectively.
  • RESULTS: Our work demonstrated that untreated patients with malignant ovarian tumors revealed significantly greater MGMT and GST activities in their sera than did both healthy individuals and patients with benign ovarian tumors, while no significant difference was found between the healthy group and the patients with benign ovarian tumors with respect to their sera MGMT and GST activities.
  • A relationship between sera MGMT and GST activities, tumor histology and pathology was not found in this study.
  • CONCLUSION: Our work suggests the fact that detection of sera MGMT and GST activities is important in diagnostic and therapeutic approaches during the course of ovarian cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Glutathione Transferase / blood. Neoplasms, Glandular and Epithelial / blood. O(6)-Methylguanine-DNA Methyltransferase / blood. Ovarian Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15734094.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; EC 2.5.1.18 / Glutathione Transferase; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


97. Wang Q, Zhang W, Li DR, Li L: [Identification of two potential serum biomarkers for ovarian cancer and clinical validation thereof]. Zhonghua Yi Xue Za Zhi; 2008 Apr 15;88(15):1012-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Identification of two potential serum biomarkers for ovarian cancer and clinical validation thereof].
  • OBJECTIVE: To identify practical biomarkers used in diagnosis of ovarian cancer.
  • METHODS: Peripheral blood samples were collected from 59 ovarian cancer patients, 64 ovarian benign tumors patients, and 142 healthy women and underwent column chromatography to purify the target proteins.
  • Receiver operating characteristic curve was drawn to examine the sensitivity and specificity of the potential biomarker to ovarian cancer.
  • The serum levels of CCL18 and CXCL1 of the patients with ovarian cancer were 150 +/- 62 ng/ml and 1 +/- 0.4 ng/ml respectively, both were significantly higher than those of the healthy control women and the patients with ovarian benign diseases (all P < 0.05).
  • The diagnostic sensitivity and specificity of CXCL1 to ovarian cancer were 100% and 97.8% respectively.
  • The diagnostic sensitivity of CCL18 was 100% to ovarian cancer of stages I-II and 86.1% to ovarian cancer of stages III-IV.
  • The model established based the combination of both biomarkers had the sensitivity and specificity to ovarian cancer of both 100%.
  • CONCLUSION: CCL18 and CXCL1 may be used in early screening of ovarian cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Chemokine CXCL1 / blood. Chemokines, CC / blood. Ovarian Neoplasms / blood
  • [MeSH-minor] Adult. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18754431.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CCL18 protein, human; 0 / CXCL1 protein, human; 0 / Chemokine CXCL1; 0 / Chemokines, CC
  •  go-up   go-down


98. Turker O, Dogan I, Kumanlioglu K: Radioiodine accumulation in a large adnexal cystadenofibroma. Thyroid; 2010 May;20(5):561-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we report a patient with marked radioiodine accumulation in a large adnexal cystadenofibroma, a benign ovarian tumor.
  • Pathologic examination revealed a benign cystadenofibroma without any coexisting thyroid tissue.
  • The mechanism for radioiodine accumulation in this patient's tumor is unclear.
  • [MeSH-major] Cystadenoma / radionuclide imaging. Ovarian Neoplasms / radionuclide imaging
  • [MeSH-minor] Carcinoma, Papillary / radiotherapy. Carcinoma, Papillary / surgery. False Positive Reactions. Female. Goiter, Nodular / surgery. Humans. Hysterectomy. Iodine Radioisotopes / pharmacokinetics. Middle Aged. Ovariectomy. Thyroid Neoplasms / radiotherapy. Thyroid Neoplasms / surgery. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20406107.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


99. Kolwijck E, Zusterzeel PL, Roelofs HM, Hendriks JC, Peters WH, Massuger LF: GSTP1-1 in ovarian cyst fluid and disease outcome of patients with ovarian cancer. Cancer Epidemiol Biomarkers Prev; 2009 Aug;18(8):2176-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GSTP1-1 in ovarian cyst fluid and disease outcome of patients with ovarian cancer.
  • We studied GSTP1-1 levels in ovarian cyst fluid (oCF), obtained during surgery before chemotherapy, of patients with epithelial ovarian cancer and clinical outcomes were correlated.
  • GSTP1-1 was determined by ELISA in oCF of 56 patients with epithelial ovarian cancer and 109 noncancer controls (21 borderline and 88 benign ovarian tumors).
  • Significantly higher levels of GSTP1-1 were found in the oCF of malignant (median, 383; range, 10-32,695 ng/mL) compared with benign (median, 20; range, 0-1,128 ng/mL) ovarian tumors (P < 0.01).
  • Significantly higher GSTP1-1 levels were found in patients with advanced International Federation of Gynaecologists and Obstetricians stage (P = 0.01), high-grade tumors (P = 0.44), and/or high levels of preoperative CA 125 (P = 0.01).
  • [MeSH-major] Biomarkers, Tumor / analysis. Glutathione S-Transferase pi / metabolism. Neoplasms, Glandular and Epithelial / enzymology. Ovarian Cysts / enzymology. Ovarian Neoplasms / enzymology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Cyst Fluid / chemistry. Cyst Fluid / enzymology. Disease-Free Survival. Enzyme-Linked Immunosorbent Assay. Female. Humans. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cysts.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661073.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; EC 2.5.1.18 / Glutathione S-Transferase pi
  •  go-up   go-down


100. Chen W, Peng P: [Expression and clinical significance of Xiap and Caspase-3 protien in primary epithelia ovarian cancer]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 Jul;26(7):673-4, 678
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and clinical significance of Xiap and Caspase-3 protien in primary epithelia ovarian cancer].
  • AIM: To study the expression and clinical significance of Xiap, Caspase-3 protein in primary epithelia ovarian cancer.
  • METHODS: The Xiap and Caspase-3 were detected by immunohistochemical in 40 cases of epithelial ovarian cancer 20 cases of borderline ovarian tumor, 15 cases of benign ovarian tumor, and 15 normal ovarian tissues.
  • RESULTS: There were significantly different between the expression of Xiap in epithelial ovarian cancer, borderline ovarian tumor, benign ovarian tumor and normal ovarian tissues.
  • The expression of Caspase-3 in epithelial ovarian cancer and borderline ovarian tumor was significantly lower than that in benign ovarian tumor and normal ovarian tissue (P<0.01).
  • The expression of Xiap in epithelial ovarian cancer was related to clinc stage, pathological grade and living.
  • The expression of caspase-3 in epithelial ovarian cancer was related to clinc stage and living (P<0.01).
  • CONCLUSION: The expressions of Xiap and Caspase-3 may be important roles for the formation and development of epithelia ovarian cancer.
  • The expressions of Xiap and Caspase-3 are the poor prognostic factors in epithelial ovarian carcinomas.
  • [MeSH-major] Caspase 3 / genetics. Epithelium / metabolism. Gene Expression Regulation, Neoplastic. Ovarian Neoplasms / genetics. X-Linked Inhibitor of Apoptosis Protein / genetics

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20862799.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / X-Linked Inhibitor of Apoptosis Protein; EC 3.4.22.- / Caspase 3
  •  go-up   go-down






Advertisement